Copyright

© Commonwealth of Australia 2022  
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au)>.

Contents

[[Message from the Deputy Secretary 4](#_Toc118290375)](#_Toc118290534)

[[Our purpose 5](#_Toc118290375)](#_Toc118290535)

[[Our vision 5](#_Toc118290375)](#_Toc118290536)

[[Our strategic framework 5](#_Toc118290375)](#_Toc118290537)

[[Measuring our performance 6](#_Toc118290375)](#_Toc118290538)

[[Priority 1 – Product regulation and safety 7](#_Toc118290375)](#_Toc118290539)

[[Priority 2 – Regulatory reform 17](#_Toc118290375)](#_Toc118290540)

[[Priority 3 – International engagement 25](#_Toc118290375)](#_Toc118290541)

[[Priority 4 – Education and compliance 32](#_Toc118290375)](#_Toc118290542)

[[Appendices 39](#_Toc118290375)](#_Toc118290543)

[[1. Prescription Medicines 39](#_Toc118290375)](#_Toc118290544)

[[2. Over-the-Counter Medicines 49](#_Toc118290375)](#_Toc118290545)

[[3. Registered Complementary Medicines 54](#_Toc118290375)](#_Toc118290546)

[[4. Assessed Listed Medicines 55](#_Toc118290375)](#_Toc118290547)

[[5. Listed Medicines 57](#_Toc118290375)](#_Toc118290548)

[[6. Biologicals and Blood Components 68](#_Toc118290375)](#_Toc118290554)

[[7. Medicine and Vaccine Adverse Event Reports 70](#_Toc118290375)](#_Toc118290555)

[[8. Medical Devices 71](#_Toc118290375)](#_Toc118290556)

[[9. Disinfectants 80](#_Toc118290375)](#_Toc118290557)

[[10. Exports 81](#_Toc118290375)](#_Toc118290558)

[[11. Access t](#_Toc118290375)[o U](#_Toc118290375)[napproved Therapeutic Goods 82](#_Toc118290375)](#_Toc118290559)

[[12. Medicines and Biol](#_Toc118290375)[ogicals Manufacturing 87](#_Toc118290375)](#_Toc118290560)

[[13. Recalls 90](#_Toc118290375)](#_Toc118290561)

[[14. Laboratory Testing 92](#_Toc118290375)](#_Toc118290562)

[[15. Regulatory Compliance 96](#_Toc118290375)](#_Toc118290563)

[[16. Pharmacovigilance Inspection Program 98](#_Toc118290375)](#_Toc118290564)

[[17. Reporting of Medicine Shortages 99](#_Toc118290375)](#_Toc118290565)

# Message from the Deputy Secretary

In 2021-22 we continued to take a lead role in adapting to the health environment that has been significantly impacted by COVID-19. Medicines and medical devices associated with COVID-19 were prioritised and their safety and efficacy assessed through stringent pre-market assessments and thorough post-market safety monitoring. Post-market review of COVID-19-related devices including face masks, respirators, and test kits was also a major activity.

During the past year, we continued to undertake our Transformation Program to streamline our business systems and modernise IT infrastructure.

From April to August 2022, the move to our purpose-built facilities in Fairbairn occurred. The new premises includes state-of-the-art laboratories to support our delivery of a world-class regulatory system for therapeutic goods. Demonstrating our commitment to a culture of staff professional development, respect, and inclusion, we continued focusing on maintaining our regulatory science capability as outlined in the *Regulatory Science Strategy 2020–2025*.

Reforms were undertaken to support emerging medical technologies such as Software as a Medical Device, while other enhancements were made to further and safeguard patients through medical device reforms. Simplified pathways and processes for industry will result in faster approval of products while maintaining our high standards of safety and efficacy. We also streamlined the Special Access Scheme and Authorised Prescriber submission processes for medicinal cannabis and made changes to the scheduling of nicotine. Further reforms were achieved by reviewing the Therapeutic Goods Advertising Code 2021.

We continued our leadership role in international collaboration to help build a more globally aligned regulatory framework by establishing legal agreements to facilitate information sharing, working as part of the leadership of the International Coalition of Medicines Regulatory Authorities to enhance cooperation and chairing the International Medical Device Regulators Forum. This work, along with our efforts to ensure safe and effective vaccines and therapeutics through our participation in the Pacific and Southeast Asia, have been driven by the *TGA’s International Engagement Strategy 2021-2025*.

Our compliance activities led to the recall of various devices and medicines including face masks, sleep therapy devices and sunscreens, along with the ongoing monitoring of signals of non-compliance with Good Manufacturing Practice.

Finally, we provided important safety monitoring and public awareness, notably in relation to COVID-19 vaccines.

**Adjunct Prof John Skerritt** FTSE FIPAA (Vic)

# Our purpose

The Therapeutic Goods Administration (TGA), as part of the Australian Government Department of Health and Aged Care, is responsible for evaluating, assessing, and monitoring products that are defined as therapeutic goods. We help Australians stay safe by regulating therapeutic goods for safety, efficacy, or performance, and quality.

We regulate the manufacture, import, export, supply and advertising of prescription medicines, vaccines, sunscreens, complementary medicines (including vitamins, minerals, herbal and traditional medicines), medical devices, blood and blood products, cellular therapies, and biologicals.

Consistent with the *Therapeutic Goods Act 1989,* we:

* apply scientific and clinical expertise to assess whether the benefits of a therapeutic good outweigh any risks to health and safety
* assess the suitability of therapeutic goods for supply, import, and export from Australia
* regulate manufacturers of therapeutic goods to ensure they meet acceptable standards of manufacturing quality
* assess the quality and compliance of therapeutic goods on the market, including through laboratory testing where appropriate
* implement a range of regulatory actions that are proportionate to the potential risk arising from non-compliance or emerging safety concerns.

We achieve this by applying risk-based processes for both pre-market assessment and   
post-market monitoring, as well as promoting regulatory compliance through clear and transparent decision-making, providing education and guidance, and using innovative technologies and ideas to streamline business functions.

# Our vision

Our vision is for better health and wellbeing for all Australians through regulatory excellence. This links directly with the Department of Health and Aged Care’s vision of better health and wellbeing for all Australians, now and for future generations.

# Our strategic framework

By regulating therapeutic goods in accordance with the *Therapeutic Goods Act 1989* and supporting regulations, we contribute to the Department’s strategic priorities:

* better health and ageing outcomes for all Australians
* an affordable, quality health and aged care system
* better sport outcomes.

We are committed to delivering our part of the Department’s Health Protection, Emergency Response and Regulation program through the protection of the health and safety of the Australian community, and the preparedness to respond to national health emergencies and risks through the regulation of therapeutic goods (including medicines, medical devices, and blood, cell, and tissue products). This applies to goods exported, imported, supplied, and manufactured in Australia.

# Measuring our performance

In line with the Australian Government’s new expectations for regulator performance and reporting, we have combined our previous KPI Performance Regulator Report and our Performance Statistics Report into this report. We will undertake our regulatory functions by applying 3 principles of regulator best practice:

**Continuous improvement and building trust**

We:

* use qualitative and quantitative analysis to assess and report on performance, and drive evidence-based continuous improvement
* promote a culture that builds public confidence in our work and trust in our decision-making.

**Risk based and data driven**

We:

* actively understand, engage with, and effectively mitigate strategic risks to successfully manage our regulatory functions without unnecessarily impeding the operations of regulated entities
* use data sources that meet relevant data assurance standards for assessing and reporting on the quality of statistical information.

**Collaboration and engagement**

We:

* seek opportunities to inform, engage and consult with our stakeholders and the Australian community
* are receptive to feedback and diverse stakeholder views
* seek to increase transparency in decision-making processes
* provide up-to-date, clear, and accessible guidance and information to assist regulated entities with compliance.

Using these 3 principles as a platform, we have outlined our performance against the strategic objectives outlined in our 2021-2022 Business Plan. Our priorities set out in the 2021-2022 TGA Annual Business Plan are:

* **Product regulation and safety** – including COVID-19 medicines, vaccines and medical devices, and digital transformation
* **Regulatory reform** – through consulting on and implementing initiatives following policy approval from government
* **International engagement** – through activities that promote international information sharing, work sharing, collaboration and regulatory convergence, as well as programs for regulatory strengthening/assistance, and medicines testing in our region
* **Regulatory education and compliance** – through education, monitoring, targeted compliance and enforcement activities and appropriate action.

## Priority 1 – Product regulation and safety

### Prioritise COVID-19 medicines and medical devices

* + 1. We continued to prioritise medicines, vaccines and medical devices that are associated with COVID-19 without compromising safety, and we worked together with our international regulatory counterparts.

The TGA remains at the forefront of the Australian Government’s response to the COVID-19 pandemic. In 2021-22 we prioritised the provisional approval of COVID-19 therapeutic goods, including:

* the approval of Moderna’s Elasomeran (SPIKEVAX) vaccine for individuals aged 18 years and older in 23 working days
* the approval of Pfizer’s Tozinameran (COMINARTY) vaccine for individuals aged 5-11 years and older in 25 working days
* the approval of Pfizer’s Tozinameran (COMINARTY) vaccine for individuals aged 12-15 years and older in 32 working days.

To further support our COVID-19 response, we developed new methods of testing for mRNA and viral vector vaccines, carried out lipid testing of mRNA-type vaccines, assessed disinfectant submissions with added COVID-19 claims, and evaluated the sterility and microbiological aspects of COVID-19 vaccines and treatments.

**Case Study – Approval of COVID-19 vaccines**

During the 2021-22 financial year we granted initial provisional approval for two COVID-19 vaccines, NUVAXOVID (Novavax) and SPIKEVAX (Moderna).

Novavax is the first protein subunit COVID-19 vaccine to receive regulatory approval in Australia. Protein vaccines use a non-infectious component found on the surface of the coronavirus and are manufactured in cells in a laboratory. After vaccination, immune cells recognise the vaccine protein as foreign and launch an immune response against it.

In contrast, the Moderna and Pfizer vaccines are a messenger RNA (mRNA) vaccine. This type of vaccine uses a genetic code called RNA to make the body's cells produce the coronavirus’ specific spike protein. The immune system cells then recognise the spike protein as a threat and begin building an immune response against it. The RNA from the vaccine does not change a person’s DNA in any way, and the body quickly breaks it down.

The decision to provisionally approve the vaccines was also informed by expert advice from the Advisory Committee on Vaccines (ACV), an independent committee with expertise in scientific, medical, and clinical fields including consumer representation.

* + 1. We supported small-to-medium enterprises (SMEs), researchers, and those unfamiliar with therapeutic goods regulation to better understand regulatory requirements.

Our dedicated service, SME Assist, has helped SMEs, researchers, start-ups and those unfamiliar with therapeutic goods regulation understand their regulatory and legislative obligations, and we published guidance on our website to provide up-to-date, clear, and accessible information to assist sponsors and manufacturers seeking approval to supply COVID-19 rapid antigen self-tests and point-of-care tests.

* + 1. We prioritised the development and approval of therapies that assist with the treatment of COVID-19. This includes advisory support to clinical trial researchers and industry, and contributions to international consortia.

In 2021-22, we provisionally approved 7 COVID-19 treatments: GlaxoSmithKline (sotorovimab), Celltrion (regdanvimab), MSD (molnupiravir), Roche (casirivimab + imdevimab), Roche (toxilizumab), Pfizer (nirmatrelvir + ritonavir) and AstraZeneca (tixagevimab and cilgavimab).

Our prioritisation of the provisional approval of these treatments is illustrated by the following examples:

* the approval of Roche Products Pty Ltd’s Tocilizumab (ACTMERA) COVID-19 treatment in 40 days
* the approval of AstraZeneca’s Tixagevimab and Cilgavimab (EVUSHELD) COVID-19 treatment, for pre-exposure prophylaxis in individuals 12 years and over, in 54 days
* the approval of GlaxoSmithKline’s Sotrovimab (XEVUDY) COVID-19 treatment in 65 days.

We continued to give priority to processing of clinical trial notifications related to COVID-19 on request from trial sponsors.

* + 1. We prioritised the regulatory review of diagnostic tests and medical devices for COVID-19 and provided advisory support to researchers and industry (including SMEs) developing medical devices and tests for COVID-19 patients.

In 2021-22 we prioritised the review of COVID-19 test kits and devices working alongside the Peter Doherty Institute for Infection and Immunity (the Doherty Institute).

|  |
| --- |
| **Case Study – Post-market review of COVID-19 related test kits and face masks**  A post-market review of all COVID-19 test kits, including Polymerase Chain Reaction (PCR) and rapid antigen tests (RATs) against COVID-19 variants of concern, including Delta and Omicron, was commenced. We engaged the Doherty Institute to undertake independent laboratory testing of COVID-19 RATs as part of the review. The review includes a total of 155 Australian Register of Therapeutic Good (ARTG) entries (244 test kits), and, as of 16 November 2022, we have received 76 test reports from the Doherty Institute. Of these, 43 of the reports have been validated by our Laboratories, and certificates of testing have been issued to sponsors and 37 results published on our website. We will continue to publish results as they become available.  Doherty Institute testing validated the sensitivity of RATs as claimed by manufacturers against guidelines set by the World Health Organisation, and testing was performed against the Delta and Omicron variants against the original SARS-CoV-2 strain. Manufacturers provided study data to validate the performance of their test kits, including recombinant protein studies, live virus studies, inactivated virus studies, and clinical studies.  We assessed pre-market applications and carried out post-market reviews of face masks and respirators. All face masks entered in the ARTG, a total of 2,276, underwent a desktop review and laboratory testing to verify their performance. This is the largest single post-market review we have undertaken. Results and findings were released to sponsors, with approximately 80% of ARTG entries cancelled due to sponsor decisions or our findings. |

* + 1. We monitored the safety and efficacy of COVID-19 vaccines through our vaccine safety monitoring system.

Our vaccine safety monitoring system rapidly detects, investigates, and responds to any emerging safety issues. We review and analyse adverse event reports, collaborate with international regulators, and review the medical literature, media, and other potential sources of new safety information as part of our surveillance activities.

During 2021-22 we processed more than 125,000adverse event reports, including more than 99,000reports for COVID-19 vaccines, with the majority submitted via the new secure file upload channel.[[1]](#footnote-2) In the same period, we investigated more than 120potential safety signals for COVID-19 vaccines, resulting in over 55 regulatory actions, including 36 safety-related Product Information updates. Outcomes were communicated to the public and health professionals via weekly updates to the COVID-19 vaccine safety report, and through regular Medicine Safety Updates on our website. As part of the pre-market Risk Management Plan (RMP), in 2021-22 we conducted 317rounds of evaluation and reviewed 318updated post-market RMPs, including for COVID-19 treatments and vaccines in short timeframes.

### Regulation of medicines and medical devices

* 1. 1. We maintained our high standards of regulation for medicines and medical devices by delivering regulatory decisions within target timeframes.

In 2021-22 we delivered regulatory decisions within target timeframes, where applicable, including:

**Prescription medicines**

* 345 submissions for new prescription medicines or variations to existing medicines that involve the evaluation of clinical, pre‑clinical or bio-equivalence data (Category 1 submissions) were approved in 2021-22, including vaccines and treatments for COVID-19[[2]](#footnote-3). The mean and median approval times in 2021-22 were 159 and 163 working days respectively, with 100% of applications processed within the legislated timeframe of 255 days[[3]](#footnote-4).

**Over-the-Counter-medicines (OTC medicines)**

* We received 196 new product applications in 2021-22, which is 17% lower than the 236 applications we received in 2020-21[[4]](#footnote-5).
* We approved 193 new N1-N5 OTC medicine applications (OTC medicine applications are categorised as new medicine (N) or change (C) applications and are further categorised by risk, with N1 low risk, N5 and C4 are highest risk) in 2021-22, which is 2% lower than the 197 we approved in 2020-21[[5]](#footnote-6).
* 803 applications to vary existing medicines were received in 2021-22, which is 10% more than the 731 applications we received in 2020-21[[6]](#footnote-7).
* 598 applications to vary existing medicines were approved in 2021-22, which is 5% higher than the 572 applications we approved in 2020-21[[7]](#footnote-8).
* The percentage of applications processed within target timeframe was 100% for N2 new product applications, and 87% and 95% respectively for C2 and C3 variation applications[[8]](#footnote-9).

**Registered complementary medicines**

* We approved 5 new registered complementary medicine applications in 2021-22, compared to 9 applications approved during 2020-21[[9]](#footnote-10). All applications were completed within legislated timeframes.

**Assessed listed medicines**

* No new assessed listed medicine applications were approved in the 2021-22 period, compared to 2 approved in 2020-21.

**Listed medicines**

* 14 new ingredients for use in listed medicines were approved in the reporting period, an increase from 5 new ingredients that were approved in 2020-21[[10]](#footnote-11).
* We completed processing 6 consent to supply applications under section 14/14A of the *Therapeutic Goods Act 1989* during 2021-22, compared to 36 applications in 2020-21. We also extended 582 existing consent applications.[[11]](#footnote-12)
* We processed 178 applications to vary existing medicines under subsection 9D(1) of the Act in 2021-22, compared to 142 applications in 2020-21[[12]](#footnote-13).
* In addition to the above approvals, 1,929 new listed medicines were entered in the Australian Register of Therapeutic Goods (ARTG) in this period, compared to 2,184 listed medicines in 2020-21[[13]](#footnote-14).

**Unapproved medicines**

* We approved 125,736 Special Access Scheme Category B (SAS B) applications and 12,172 Authorised Prescriber (AP) applications during 2021-22[[14]](#footnote-15). Approvals increased by 15.7% and 125% respectively compared to 2020-21, when we approved 108,674 SAS B applications and 5,398 AP applications. The significant increases are primarily due to the sustained growth in SAS and AP applications for medicinal cannabis products.
* 239 SAS B applications for biological products in 2021-22 were approved, which is a 40% decrease compared to 399 applications approved during 2020-21[[15]](#footnote-16).

**Medical devices**

* We processed 7,624 medical device (including In Vitro Diagnostic devices), disinfectant and variation applications in 2021-22, and 6,120 applications were approved.
* We granted 278 conformity assessment certificates to manufacturers of medical devices in 2021-22,[[16]](#footnote-17) certifying that those devices meet fundamental safety and performance standards.
* The mean and median processing timeframes for conformity assessment applications were 139 and 168 business days respectively[[17]](#footnote-18). 100% of applications were processed within the legislated timeframe of 255 days.

**Laboratory testing**

* Laboratory staff continued to be directly involved in providing advice and developing strategies around various COVID-19-related issues, specifically vaccines, hand sanitisers, ventilators, disinfectants, and Personal Protective Equipment (PPE), as well as assisting other areas of the Australian Government.
* We tested 1,738 medical devices in 2021-22, which is a 210% increase from the 827 devices tested in 2020-21. This was predominantly due to the testing of face masks, respirators, and COVID-19 Rapid Antigen Tests (RATs) included in the ARTG, and testing conducted to support Commonwealth, state, and territory procurement activities[[18]](#footnote-19).
* Review statistics regarding face masks are as follows:
  + As of 30 June 2022, there are 2,276 ARTG entries included in the face mask review, of which:
    - 1,364 face mask entries were cancelled by the sponsor
    - 445 face mask entries were cancelled by a delegate of the Secretary.

**Inspections**

* Much of our work program continued to be shaped by COVID-19, with a focus on inspections and assessments for vaccines and treatments for Australia and the Indo-Pacific region.
* We undertook 104 overseas remote Good Manufacturing Practice (GMP) inspections[[19]](#footnote-20) and 139 domestic GMP inspections[[20]](#footnote-21) (which were performed remotely or a combination of remote and onsite components) in 2021-22, compared to 54 overseas inspections and 210 domestic inspections undertaken in 2020-21. GMP describes a set of principles and procedures that when followed helps ensure that therapeutic goods are of high quality.
* We recommenced onsite overseas inspections in June 2022 using a risk-based approach and conducted one vaccine-related inspection.

**Licensing and clearance**

* During 2021-22 we expedited the processing of licensing and clearance applications, processing 571 GMP applications, issuing 14 new licenses, varying 129 GMP licenses and issuing 178 GMP certificates, compared to 928 GMP applications processed, 13 new licenses issued, 233 GMP licenses varied, and 154 GMP certificates issued in 2020-21.
* We assessed 8,902 GMP clearances and approved 8,103 in 2021-22, in comparison to assessing 7,302 clearances and approving 6,778 in 2020-21[[21]](#footnote-22). GMP Clearance is required to determine whether overseas manufacturing sites comply with the principles of GMP for products being supplied to Australia.

**Recalls**

* In 2021-22 we coordinated 819 recall actions compared to 880 actions in 2020-21[[22]](#footnote-23). Recall actions involved global corrective actions for millions of sleep therapy devices, multiple medical device recall actions following the revelation of falsified sterility data, and the recall of a popular brand of sunscreen due to the presence of benzene.
  + 1. We have responded to scientific advancements and emerging technologies to support timely access to new therapeutics.

Advances in technology and software production have led to a large increase in Software as a Medical Device (SaMD) products on the market, requiring greater clarification of the regulatory requirements to ensure patient safety. SaMD encompasses various applications, such as mobile applications to analyse rapid antigen tests to detect COVID-19 and systems that diagnose tumours from radiology images, many of which use Artificial Intelligence.

|  |
| --- |
| **Case Study – Software as a Medical Device (SaMD) reform project**  In 2021-22 the government refined and clarified the regulation of software based medical devices, including software that functions as a medical device in its own right (SaMD). SaMD refers to various technologies including mobile applications, web applications, server-based systems, traditional desktop packages, cloud-based systems, or any combination of these. Since February 2021, we have engaged industry extensively to develop detailed guidance to assist many new developers who are now sponsors, as well as providing educational webinars, some of which were delivered by ANDHealth for the sector regarding:   * the boundaries of regulation for software and excluding some products that are low risk or where there are alternative oversight mechanisms. To avoid unnecessary regulatory oversight, certain clinical decision support software was excluded, where there is no significant risk to safety, and they met certain criteria * new classification rules for programmed and programmable medical devices and software that diagnose, monitor, or treat diseases and conditions * amendments to existing requirements in the Essential Principles from the *Therapeutic Goods Act 1989* in relation to cyber security, management of data and information, and requirements relating to development, production, and maintenance to provide greater clarity. |

* + 1. We continued to improve the transparency of our activities.

During the COVID-19 pandemic we experienced unprecedented public interest regarding the safety of medicines and vaccines, with large numbers of people searching our website for information about adverse events. We received an increase in reports of suspected adverse events, from 59,639 notifications received in 2020-21, to 125,873 received in 2021-22[[23]](#footnote-24). The increase in the number of adverse event reports and traffic on our website resulted in database performance issues, including time-outs and the inability to download search results.

To maintain transparency of medicine and vaccine adverse events, we created a trial (beta) version of the Database of Adverse Event Notifications (DAEN) for medicines. The beta version includes interactive tables and graphs, a mobile-friendly interface, and additional data download functions, improving how this information is displayed on our website.

There were 39 consultations opened in 2021-22 via the TGA Consultation Hub. These consultations covered many topics of regulation, including adoption of international scientific guidelines in Australia, amendments to the application process for inclusion of Class 1 medical devices, repurposing medicines, and improving patient access to critical medicines in acute-care settings. Our consultation process is a critical mechanism of informing regulatory reforms and policy changes for consideration by government.

**Case Study – Repurposing of medicines second public consultation**

The repurposing medicines consultation received 27 responses from patients and patient groups, health professionals, academia, and the pharmaceutical industry. We received important advice including:

* clarification regarding data sharing and ownership, regulatory, manufacturing, and operational responsibilities, as well as cost sharing that will be required when repurposing off-patent medicines
* making the patient voice a priority
* rare diseases and unmet needs should be focus areas
* real-world data insights should be considered early in the process of prioritisation
* a streamlined process with simpler data requirements would reduce the burden on sponsors when applying for the repurposed indication.

Feedback from this consultation is now shaping regulatory reforms for consideration by government.

### Capability development

1.3.1. The Regulatory Science Strategy 2020-2025 aims to make sure that we continue to make the best possible regulatory decisions, by ensuring that our regulatory scientists are capable, collaborative, communicative, and responsive to future challenges and emerging technologies.

The first key focus area of the Regulatory Science Strategy is to ‘maintain and build skills in regulatory science’. To provide training and development opportunities that allow our staff to maintain their scientific expertise and further develop their skills to meet future challenges, we:

* developed formal induction e-learning modules
* rolled out the Regulatory Scientist Capability Framework across our Medicines Regulation Division to support consistency in job descriptions
* developed a Continued Development Framework to empower staff and managers to maintain their technical and regulatory skills.

We also shifted resources to ensure that our regulatory scientists are capable, collaborative, communicative, and responsive to future challenges and emerging technologies, in line with the Strategy.

### Digital transformation

* 2. 1. The four-year digital transformation program will deliver simpler, faster, and more secure interactions between industry and government to apply for, track, pay, and manage regulated and subsidised health-related products and services.

Our Transformation Program made progress across several initiatives this year, to reduce the regulatory burden on industry and improve access to information for health providers and consumers. We conducted consultations with internal and industry stakeholders over the past year to define current prescription medicine processes, identify common difficulties and ‘pain points' that stakeholders experience, and suggest potential solutions to those issues. The recommendations from the user research were:

* user journeys across the website and transaction portal
* recognise different usage patterns, for example where infrequent use equals “first time, every time”
* provide support channels to improve the quality of applications, self-service, and reduce burden on our resources
* use service channels most relevant for the audience, such as website, portal, Electronic Data Interchange (EDI), and other external channels
* consolidate existing portals into a single point of contact
* present information and services tailored to the audience
* use analytics to inform decisions, such as prioritising which services to uplift to the new portal.

This feedback has been incorporated into the Transformation Program planning to build new TGA services in the Health Products Portal.

The proposed single point of entry will allow quick and easy access for stakeholders to apply for products to be included on the ARTG. The new portal aims to streamline the application process, support users to manage their applications and make payments, while increasing the transparency of the progress of an application in the assessment process.

* + 1. We continued to modernise our services (eBusiness Services/TGA Business Services), and the redevelopment of the ARTG, as well as making enhancements to support reporting and sharing of adverse event data for medicines and vaccines.

The program to modernise our service experience began with user research to better understand the preferred experience of our customers. Milestones included the release of an updated public portal for advertising compliance and improvements to ARTG searching. The updated features of the portal include:

* new forms to facilitate reporting of non-compliance and advertising enquiries
* applications to use restricted representations in advertising
* a newly launched trial ARTG public search tool to make information easier to find.

We have also progressed improvements to how we share and receive medicine and vaccine adverse event reports. Based on feedback from public consultation, we created the ability for sponsors to access adverse event reports relevant to their medicines using their existing log-in details. This will replace the need for sponsors to email us to request reports, delivering better and faster access to relevant adverse event data with less effort.

We have investigated how we can make it easier for health professionals to report adverse events to us by investigating options for embedding reporting in General Practitioner practice management software. We sought opportunities for collaboration and engagement by liaising with health professionals regarding their requirements, and by consulting software vendors to ascertain the possibilities for the software.

* + 1. We redeveloped our website and repositioned it onto the GovCMS platform, while ensuring a consistent user experience across all our digital channels.

As part of the digital transformation, in order to launch our new website, more than 110 web content types and topics were assessed, more than 4,000 old web content pages were archived, and approximately 1,250 people were consulted. This has allowed us to deliver improvements to:

* the website interface and functionality, to make it easier to find and understand the information required by users
* navigation and search enhancements to provide quicker search results
* move old website content to be archived on the National Library of Australia web archive, TROVE.

Following these actions, the new website was launched on 30 August 2022, with a modern and simple interface and improved search function. While the new website addresses many straightforward enquiries, more complex enquiries will still come through to our enquiry channels.

Some stakeholders have told us they have experienced challenges getting the information they need when contacting us or have experienced delays in receiving a response. To help address these concerns, we are undertaking an enquiry management project that will modernise our enquiry channels. In 2021-22, we completed the ‘discovery’ phase of the project and gained a better understanding of how enquiries are handled and the gaps in our existing processes.

* + 1. We continued to implement a new system for medical device post-market reviews and improving timeliness and the detection of potential safety problems.

We have managed an increased number of systematic medical device post-market reviews. An enhanced IT system was implemented to support more efficient submission of evidence and tracking of reviews.

In addition, we undertook further preparation for the introduction of a Unique Device Identifier (UDI) System, with a plan for voluntary use of UDI in 2023. The UDI system will allow tracking and tracing of medical devices including those that have been implanted in patients if the UDI is used throughout healthcare and supply chains. This will allow doctors to notify patients quickly if there is a medical device safety issue.

### New state of the art laboratories

After 30 years in Symonston, we relocated to new premises in Fairbairn, also in the ACT, in 2022. The location comprises 2 purpose-built buildings – an office building and a dedicated laboratory building. Most of our staff relocated between April and June, with the Laboratories Branch relocated in August. The laboratories have been constructed specifically to meet our requirements. The transition was undertaken as planned to minimise the impact on the output of the laboratories and the timeliness of regulatory decisions and safety monitoring actions upon moving. The custom-built laboratories will help maintain our reputation as a world-class regulator by enabling continuous improvement and building trust, risk-based and data-driven regulatory practices and promoting collaboration and engagement.

## Priority 2 – Regulatory reform



### Prescription medicines

1. 1. 1. We implemented a risk-based program of Good Clinical Practice inspections of Australian clinical trials of medicines and biological products

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials. Compliance with GCP provides assurance that the rights, safety, and well-being of clinical trial participants are protected and that the trial data generated are credible.

Clinical trials of medicines and biologicals are regulated under the Clinical Trial Notification (CTN), or Clinical Trial Approval (CTA) schemes, both of which are subject to our GCP Inspection Program. We have published guidance on the GCP Inspection program on our website to provide sponsors with further information about the program's scope and process. This guidance describes how we prioritise and schedule GCP inspections, the kinds of inspections we might conduct, the inspection process, and how we report and follow-up on inspection.

We also held a series of webinars introducing the GCP inspection program in May-June 2022, following publication of guidance on the program. The webinars reached over 1,200 participants who were interested in learning about how we verify that clinical trial sites are compliant with Australian and internationally accepted standards.

* + 1. We updated the Pharmaceutical Inspection Cooperation Scheme (PIC/S) guidance to reflect current best practice for requirements for medicines manufacturing quality.

We use internationally harmonised manufacturing standards, such as the PIC/S Guide to GMP, to allow manufacturers to operate in an international environment. Throughout 2021-22, we have been very active in improving the global framework for regulating manufacturing standards for medicines, by leading or participating in working groups of the PIC/S. These include the PIC/S working groups on inspection reliance, remote assessments, and Annex 1, as well as the Expert Circle on Quality Risk Management and cross contamination in shared facilities.

Following a consultation process in 2021-22 with stakeholders in the TGA Industry Working Group on GMP, we adopted the PIC/S guide to GMP version 15 on 1 July 2022. The adoption process involved assessment of the key changes with the new Annex 2A for the manufacture of advanced therapy medicinal products for human use and minor edits to Annex 2B for the manufacture of biological medicinal substances and products for human use which was previously Annex 2.

### Complementary medicines and sunscreens

* 1. 1. We developed mandatory requirements for ingredient applications for listed medicines to provide transparency to applicants on the information we require, and to enable more efficient screening and evaluation of these applications.

During 2021-22 we continued to review and address industry feedback to finalise mandatory requirements and associated guidelines when applying for a new substance for use in listed medicines. In response to industry feedback, we also developed new compositional guideline templates and refined draft guidelines for microorganism characterisation for listed and registered complementary medicines.

Following industry and public consultation, including 2 industry webinars, we published revised Evidence Guidelines for Listed Medicines. The revised Guidelines provide greater clarity regarding:

* the purpose of the Guidelines
* the legislative basis for requiring efficacy for listed medicines
* evidence sources for traditional medicines
* efficacy expectations
* evidence requirements for supplement indications
* further explanation on what we consider is a critical appraisal.
  + 1. We considered approval pathways for sunscreen active and excipient ingredients to provide transparency to applicants on the information required by us, and to enable more efficient screening and evaluation of these applications.

The safety and quality data requirements for new sunscreen active and excipient ingredients were reviewed, and after considering industry feedback, these requirements were appropriately adjusted to address their topical dosage form. We also drafted amendments which allows for expanded use of Comparable Overseas Bodies evaluation reports, thereby supporting abbreviated evaluations of applications for new sunscreen active and excipient ingredients.

* + 1. Further enhancement of the listed medicines post-market compliance scheme as part of our digital transformation project.

During 2021-22, a greater number of targeted compliance reviews were conducted based on signals intelligence received through various avenues such as complaints, pro-active scanning of the ARTG, referrals from other agencies, actions from international counterparts, adverse events and our laboratory testing results.

We conducted weekly ARTG scanning of newly listed medicines to detect potential non-compliance of a medicine prior to the sponsor marketing the medicine. Early engagement with the sponsor soon after their listing also allows sponsors to update their product before they suffer commercial losses. Signals of potential non-compliance were triaged and assessed for alleged breaches and actions taken were dependent on the risks posed. Actions from signals ranged from educational correspondence, warning letters and compliance reviews to infringement notices. 2,115 newly listed medicines were monitored via ARTG scanning, with 221 risk-assessed for potential compliance issues. 19 were deemed to be signals of potential non-compliance and were further investigated.[[24]](#footnote-25)

During the reporting period we introduced new internal work management pathways to better capture complaint and referral actions, which enabled us to effectively track low-level compliance actions and outcomes and build sponsor compliance profiles.

Targeted reviews in 2021-22 included medicines containing safrole, caffeine and vitamin A, medicines that required warnings for use during pregnancy and sunscreen products. Indications targeted included COVID-19, arthritis, and serious gastrointestinal conditions. In addition, a sponsor with a long history of non-compliance was targeted.

We publish results of all listed medicine compliance reviews in a database on our website which allows consumers to make more informed choices about the efficacy and safety of their medicines. The searchable database includes information about whether a medicine can continue to be used safely as directed, the recommended actions for consumers to take in relation to the medicine, and our findings relating to the safety and efficacy of the medicine. We published 78 compliance reviews in 2021-22.

* + 1. With changes to the regulation of sports supplements, we undertook a comprehensive compliance program.

We undertook compliance actions under the Sports Supplements Compliance Plan including an intelligence review to identify non-compliance cases, laboratory testing of over 20products, finalising existing investigations, launching a civil action, and running cases/investigations with the regulatory response to be determined, proportionate to the behaviour and investigation outcomes.

### Medical devices

* 1. 1. We completed the implementation of business processes to enable Australian Conformity Assessment Bodies (CAB) to provide conformity assessment for medical devices.

Since 1 July 2021 we accept conformity assessment documents issued by an Australian CAB including those issued for medical devices that contain medicines or materials of animal, microbial, recombinant, or human origin; and Class 4 in vitro diagnostic (IVD) medical devices. We published external guidance and the application form in July 2021 to allow applicants to apply to become an Australian CAB.

* + 1. We implemented the reclassification of devices to align with the European Union Medical Device Reforms where appropriate.

Following extensive reviews and public consultation, we implemented the reclassification of certain medical devices to align with changes being adopted under the European Union (EU) Medical Device Regulations (where appropriate).

Actions include:

* regulatory changes to the definition and scope of medical devices
* development of medical device patient information materials
* refinements to the definition for systems or procedure packs
* community expectations for regulatory oversight of medical device clinical trials
* reclassification of surgical mesh.

Reclassification of 6 categories of medical devices to align with the EU's Medical Device Regulations came into effect on 25 November 2021.

Given the significant changes in the EU framework, other changes in Australia have meant decreased regulatory burden as some processes have been further streamlined to a risk-based approach to reviewing applications rather than a mandatory approach.

* + 1. We undertook further preparation for the introduction of a Unique Device Identifier (UDI) system.

We undertook further preparation for the introduction of a UDI System, with release of a “sandpit” version of the UDI database in mid-2022 for stakeholder feedback and for voluntary use by sponsors and manufacturers to submit data in 2023. Several pilot sites being negotiated with hospitals will also be critical to the implementation of the UDI. The UDI will improve patient safety and post market surveillance when fully adopted in supply chain, clinical and other health systems, by enabling easier and faster identification of patients who have been implanted with a device of concern (a device with a safety incident or recall related to that device), and easier identification and removal of those devices from stocks, storage, and distribution, helping prevent any further devices of that model being implanted or used. The UDI will also allow patients, consumers, and health professionals to easily access information about the devices that they use, including if there is a device safety incident or recall related to that device.

In progressing the UDI implementation, we sought industry feedback through a range of forums and consultations and delivered a series of webinars on the Australian UDI system. The engagement has provided feedback on the considerations for the Australian UDI, including global alignment, Global Medical Device Nomenclature (GMDN), challenges for the implementation of UDI by healthcare providers, and data elements. Among other benefits, the implementation of UDI will allow more accurate identification of medical device models in reports and complaints received by us.

* + 1. We have continued to improve post-market monitoring systems for medical devices, including implementing methods for early detection and action on emerging safety issues, thereby allowing us to notify consumers earlier.

We participate in regular meetings with international medical device regulators to exchange signals and concerns in relation to medical device safety and quality signals. This allows us to identify and evaluate issues experienced internationally and instigate action even if the signal has not emerged locally. In addition, we are exploring data analytics capability to identify emerging trends and signals from the reporting of adverse events.

Further, we have reviewed the current rules that exempt manufacturers from reporting adverse events in some circumstances and will consult with stakeholders on any proposed changes. Proposed changes will improve the reporting of adverse events and enable earlier detection of signals. Additionally, in November 2021 we commenced the development of a new medical device sponsor vigilance program which will help us verify and educate sponsors compliance with legislative requirements. A pilot program is scheduled to commence in 2023.

* + 1. We have continued to implement the Action Plan for Medical Devices.

Following on from the publication in 2019 of the Action Plan for Medical Devices, we have undertaken numerous activities in order to improve the process for devices gaining access to the market. These include:

* webinars and stakeholder workshops regarding the approaches to handling the transitioning and assessment of medical devices approved under the EU Medical Devices Directive (MDD)
* new applications under the new EU Medical Devices Regulations (MDR)
* the re-classification of certain medical devices.

These devices include:

* active medical devices for therapy with diagnostic function
* spinal implantable medical devices (motion preserving)
* devices used in direct contact with the heart, central circulatory system, or central nervous system
* medical devices that administer medicines or biologicals by inhalation
* active implantable medical devices
* medical devices that are substances introduced into the body via body orifice or applied to the skin.

We have published:

* guidance for industry relating to regulatory amendments for first aid kits and system or procedure packs
* guidance on regulations of software and applications which meet the legislative definition of a medical device in Australia
* guidance and sponsor notification forms for the 5 reclassified medical devices
* updated guidance for the personalised medical devices sector
* guidance regarding requirements for Patient Information Leaflets (PILS) and Patient Information Cards (PICs).

Five working groups with consumer representation have been established and have been meeting regularly during the reporting period, including the Breast Implant Expert Working Group, the Medical Device Consumer Working Group, the Women’s Health Products Working Group, the Ventilator Expert Working Group, and the Surgical Mesh Expert Working Group.

Fact sheets have been published to provide information and assist consumers, healthcare professionals, and industry, including the digital mental health fact sheet, breast implant associated-anaplastic large cell lymphoma (BIA-ALCL), purchasing approved RAT kits/self-tests and COVID-19 self-testing on correct use of these tests.

On 29 October 2021, amendments to the Therapeutic Goods (Medical Device) Regulations 2002 came into effect, allowing greater flexibility in how patient information materials can be supplied with implantable and active implantable medical devices in Australia.

* + 1. Conducting public consultations, we provided advice to government on the:
* **requirements for medical devices used in clinical trials**
* **potential inspections of the systems used by sponsors for reporting and tracking adverse events**
* **enhancements to adverse event reporting, including whether adverse event reporting by healthcare facilities should be mandated.**

We regularly meet with state and territory health departments to discuss matters including COVID-19 RATs, Personal Protective Equipment, and other regulatory actions relating to medical devices. A suite of measures has commenced to enhance the post-market adverse event reporting and surveillance of medical devices.

In late 2022 we undertook a public consultation on proposed regulatory changes to strengthen safety oversight of clinical trials for medical devices.

Further examples of other measures taken include working with the Australian Commission on Safety and Quality in Health Care (ACSQHC) to explore ways to implement the mandatory reporting of adverse events by healthcare facilities, improving the ways to report adverse events (including possible use of smartphone applications), reviewing adverse event reporting exemption rules, a medical device vigilance program, a pilot program to enable auditing and inspection of medical device sponsors (Unique Identifier System) and ongoing monitoring to support the re-classification of surgical mesh.

In December 2021 we published a discussion paper on Mandatory Reporting of Medical Device Adverse Events by Healthcare Facilities for public feedback. We are now preparing options to implement the scheme, in partnership with states and territories and the ACSQHC.

### Medicines and Chemicals Scheduling

* 1. 1. We ensured that the implementation of changes to the scheduling of nicotine for use in e-cigarettes are adequately supported by related regulatory change, stakeholder interaction and communication once changes came into effect in October 2021.

On 1 October 2021, the scheduling was amended to make all Nicotine Vaping Products (NVPs) prescription-only medicines. This had the effect of preventing, under the Therapeutic Goods Act 1989, individuals from legally buying NVPs (such as nicotine e-cigarettes, nicotine pods and liquid nicotine) from overseas websites without first getting a prescription. This aligned Commonwealth legislation with existing state and territory laws that prevented the domestic supply of NVPs to consumers without a prescription.

To adequately support the changes, we:

* delivered an educational campaign to inform stakeholders about the changes to how NVPs can be accessed, prescribed, and supplied in Australia
* following public consultation, we made a product standard to set minimum safety and quality requirements for NVPs (Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021)
* progressed amendments to the Therapeutic Goods Regulations 1990 to facilitate pharmacies stocking unapproved NVPs in their dispensaries in anticipation of prescriptions and our required approvals
* granted a legal permission which allows pharmacies and pharmacy marketing groups to advertise (subject to certain strict conditions) where an individual may obtain NVPs with a prescription (to facilitate consumers accessing NVPs through lawful channels). We analysed vaping and e-cigarette import data over a 12-month period and established risk ratings for known importers and suppliers - the intelligence assessment formed part of the broader compliance response to the October 2021 nicotine scheduling changes, which included targeted education initiatives and monitoring activities for border compliance.
  + 1. We worked with stakeholders to develop a new application form for proposing scheduling changes and a database to make the Poisons Standard publicly searchable.

We met with representatives from each state and territory, to introduce an exposure draft of the Poisons Standard. We worked with the Office of Parliamentary Counsel to modernise the Poisons Standard to meet current legislative drafting standards, ahead of implementation of the Standard in early 2023. As a result, the modernised Standard will be easier to navigate and understand and will support the development of a searchable Poisons Standard database. After input from stakeholders, the online application form will be operational in 2022-23.

* + 1. Together with major stakeholders, we considered improvements to ‘Appendix M’ of the Standard to facilitate down-scheduling of appropriate prescription-only substances to pharmacist-only.

Appendix M of the Poisons Standard is intended to include substances that have formerly been scheduled as Schedule 4 (S4) and thus have required a prescription by a medical practitioner, but if rescheduled to Schedule 3 (S3) could be dispensed by a pharmacist with specific controls in place that help appropriate use.

There has been no progress during 2021-22, but improvements targeted to improve Appendix M in the Poisons Standard will continue to be considered into 2023.

### Medicinal Cannabis

* 1. 1. We progressed reforms and improved business processes to the regulation of medicinal cannabis products in Australia, including requirements relating to supply, manufacture, labelling and packaging.

We implemented reforms to the patient access framework in November 2021, streamlining the Special Access Scheme (SAS) and Authorised Prescriber (AP) submission process by accepting ‘unapproved’ medicinal cannabis applications under active ingredients rather than brand name. The reforms aimed to reduce prescriber administrative burden and further improve patient access by enabling continuation of therapy in the event of a product shortage or discontinuation, or when a decision is made to switch to another equivalent product for reasons such as cost.

Access to certain medicinal cannabis products was streamlined through inclusion in the AP ‘Established History of Use’ pathway by reference to active ingredient categories, dosage forms and indications. When using this pathway, prescribers do not require Human Research Ethics Committee approval or specialist college endorsement by applying to us to become an AP.

In addition, significant enhancements were progressed to the SAS/AP Online System to support the uptake of the AP pathway, including improvement to the usability of the system and improvements to the mandatory six-monthly reporting functionality to better meet prescriber reporting needs.

The Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017 is a standard that specifies minimum quality requirements for unapproved medicinal cannabis products imported into and supplied or manufactured in Australia, and the Order was amended in March 2022, with most of the changes applying to medicinal cannabis products released for supply on or after 1 July 2023.

The government endorsed regulatory reforms to medicinal cannabis manufacturing, labelling, and packaging requirements, requiring overseas manufacturing of medicinal cannabis to hold evidence of Good Manufacturing Practice (GMP) compliance. Australian manufacturers must operate in compliance with the Australian Code of GMP for medicines and be licensed by us.

In addition, labels are required to clearly differentiate between medicinal cannabis products that are based on plant material, broad spectrum extracts, full spectrum extracts and isolates (of the active ingredient). Different information is required in each case - more information is required for active ingredients that are not present as isolates. Labelling requirements aim to help prescribers and consumers identify the goods and know how to use and store them safely. Products must also have child-resistant packaging when there is a high risk associated with accidental ingestion. These reforms provide greater protection to patients by broadly aligning GMP for imported products with those that already apply to domestically manufactured goods.

## Priority 3 – International engagement

The TGA’s International Engagement Strategy 2021-2025 describes how working with our international regulatory counterparts will benefit Australians through a more globally aligned regulatory framework. Reduced regulatory burden on industry, a fit for purpose regulatory system that is responsive to the latest medical and scientific developments and enhanced global identification of safety signals leads to improved access to health products and better safeguards for the Australian community.

The strategy consists of 4 goals:

* Goal 1: Build a globally aligned regulatory framework that fosters sovereign decision making.
* Goal 2: Pre-market global collaboration and information sharing with comparable overseas regulators to reduce regulatory burden.
* Goal 3: Post-market global surveillance utilising international networks to monitor product safety and quality and maintain supply chains.
* Goal 4: Strengthen regional regulatory capabilities for safer and effective therapeutics.

### Activities during 2021-22

1. 1. 1. Goal 1. Build a globally aligned regulatory framework that fosters sovereign decision making.

**Legal agreements to facilitate information sharing**

Establishment of legal agreements with our international regulatory counterparts ensures Australia’s access to quality, safe and effective therapeutic goods is maintained when sharing confidential information. We currently have 30 agreements for confidential information sharing in place with regulatory authorities in 25 countries and are a party to 5 treaty-level country mutual recognition agreements. Two new agreements were established in this reporting period:

* TGA – Swedish Medicines Products Agency Agreement for confidential information sharing on regulation of medical devices (signed 9 June 2022)
* TGA – Brunei Darussalam Medicines Control Authority Memorandum of Understanding for sharing of confidential information (signed 26 September 2022).

|  |
| --- |
| **Case Study – TGA-Brunei Darussalam Medicines Control Authority MoU**  The TGA signed a Memorandum of Understanding (MoU) with the Brunei Darussalam Medicines Control Authority (BDMCA) at a virtual signing event on 26 September 2022, following TGA approval of the MoU on 9 June. The MoU was jointly signed by the Chairman of the BDMCA and the Deputy Secretary, Health Products Regulation Group, and witnessed by the Permanent Secretary, Brunei Ministry of Health. The Australian High Commissioner to Brunei was present at the signing.    Brunei officials noted the MoU’s support for information exchange on the regulation of therapeutic products, and the enhanced opportunities for the exchange of information on the regulatory framework of pre- and post-market products. The MoU is a great example of work under our international engagement strategy and will contribute to capacity building for BDMCA health professionals.  The development of the MoU was strongly supported by the Department of Foreign Affairs and Trade (DFAT) and the Australian High Commission in Brunei, with the emergence of the COVID-19 pandemic. Australia also supported Brunei with 100,000 doses of Australian-made VAXZEVRIA under an Emergency Use Authorisation. Additionally, DFAT worked closely with Brunei during its ASEAN (Association of Southeast Asian Nations) Chairmanship year in 2021 to address the impacts of COVID-19 on mental health, and co-sponsored Brunei’s East ASEAN Summits Leaders’ Statement on Mental Health Cooperation and Workshops in November 2021. |

**Interactions with our international regulatory counterparts**

From 3-5 November 2021, we hosted a series of interactive presentations on Good Manufacturing Practices for vaccines and biological medicines for the Thai Food and Drug Administration. The training material was delivered in Thai and the sessions were productive and collaborative.

As part of the Free Trade Agreement negotiations between Australia and India, on 1 March 2022 we hosted a delegation of Indian Government commerce, trade, regulator, and pharmaceutical industry officials to discuss opportunities for closer regulatory collaboration with the TGA.

In May 2022, we met with the South African Health Products Regulatory Authority (SAHPRA) to provide advice in developing its regulatory capabilities and procedures. We have since set up a future meeting to continue to provide our support in these areas.

We also participated in the World Health Organisation global benchmarking tool assessment of the Republic of Korea’s regulator in May 2022.

**International Medical Device Regulators**

The International Medical Device Regulators Forum’s Working Group on Personalised Medical Devices (PMDs), chaired by the TGA, developed guidance documents for providing harmonized recommendations for the regulation of PMDs, including for regulation of their point-of-care manufacture.

* + 1. Goal 2. Pre-market global collaboration and information sharing with comparable overseas regulators to reduce regulatory burden.

**International Coalition of Medicines Regulatory Authorities**

The International Coalition of Medicines Regulatory Authorities (ICMRA) was established to better safeguard global public health by facilitating greater cooperation. It enables Heads of Medicines Regulatory Authorities to exercise concerted strategic leadership during a global public health crisis and shared regulatory issues and challenges.

Since the start of the COVID-19 pandemic, international collaboration between regulators has been critical to Australia’s response. As Vice Chair of ICMRA, we played a leading role. Interactions through email have occurred daily, and by videoconference weekly, for much of the pandemic, and we have shared information in ‘real time’ as well as collaborating formally on product reviews and important safety concerns. As a relatively small regulator, Australia has received far more information than we have contributed, though we have played a global leadership role in chairing/co-chairing the main global initiatives, building robust processes for international collaboration, and leading initiatives on vaccine safety and vaccine communication as chair of the Vaccine Pharmacovigilance Network (VPN).

**International work-sharing for prescription medicines and medical devices**

Access Consortium

The Access Consortium is a medium-sized coalition of like-minded regulatory authorities (Australia-Canada-Singapore-Switzerland-United Kingdom) that work together to promote greater regulatory collaboration and alignment of regulatory requirements. One significant area of collaboration is work-sharing the evaluation of a wide range of new chemical entities and generic medicines which streamline the evaluation process and reduce duplication of evaluation effort.

The Access Consortium has several active working groups in place and participates in work-sharing initiatives for the following:

* In 2021 we chaired the Access Consortium Generic Medicines work-sharing initiative
* In 2021 we chaired the Access Consortium Biosimilars work-sharing initiative
* In 2021-22 we chaired the Access Consortium New Active Substances (NAS) work-sharing initiative, along with the COVID-19 Vaccines and Therapeutics Working Group (CVTWG).

In 2021-22, 12 submissions were approved through the NAS and 4 submissions were approved through the Access Generic Medicine Work-Sharing Initiative.

Project Orbis

Project Orbis is led by the US Food and Drug Administration (FDA) and provides a framework for concurrent submission and parallel review of oncology products among international partners, currently Australia (TGA), Canada (Health Canada), Switzerland (Swissmedic), Singapore (HSA), Japan (PMDA) and Brazil (Anvisa). During 2021-22, 22 submissions were approved through Project Orbis.

International agreements and arrangements for Good Manufacturing Process (GMP) clearance

We have entered into various international agreements and arrangements with other countries and regulatory authorities to support international collaboration in the manufacturing of medicines. Some of these agreements and arrangements allow us to use inspections conducted by these regulatory authorities as part of the GMP clearance process in lieu of performing our own on-site inspection. Many regulatory authorities, including the TGA, are members of the Pharmaceutical Inspection Cooperation Scheme (PIC/S), which is a non-binding, informal, cooperative arrangement between the authorities that regulate GMP for medicinal products.

International Medical Device Regulators Forum

Although only a medium sized regulator, we were one of the founding members of the International Medical Device Regulators Forum (IMDRF) in 2011 and very much helped shape IMDRF and its programs. IMDRF builds on the strong foundational work of the Global Harmonization Task Force on Medical Devices and aims to accelerate international medical device regulatory harmonisation and convergence to promote an efficient and effective medical devices sector.

During 2022 we chaired and operated the secretariat for IMDRF. As part of this role, we hosted 3 virtual IMDRF Management Committee meetings in January, April, and June 2022, and ran the hybrid IMDRF 22nd Management Committee Meetings in Sydney in September 2022. This is an important global event for the medical device industry and regulators with over 500 registrants from 41 countries expected to attend in-person or virtually, including representatives from 21 regulatory authorities. Standards for Health Software and Artificial Intelligence in Medical Devices were the focus for the industry stakeholder workshops in 2022.

We continued our leadership of the IMDRF Personalised Medical Devices (PMD) Working Group. The Group is responsible for developing guidance documents and recommendations for harmonising the regulation of PMDs. The work of the working group can be viewed on the IMDRF website.

* + 1. Goal 3. Post-market global surveillance utilising international networks to monitor product safety and quality and maintain supply chains.

**International Coalition of Medicines Regulatory Authorities Vaccine Pharmacovigilance Network**

We continue to co-chair the International Coalition of Medicines Regulatory Authorities (ICMRA) COVID-19 Vaccine Pharmacovigilance Network (VPN) together with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) which meets regularly to share knowledge, experience and communications on pharmacovigilance activities and the emerging benefit-risk profile of COVID-19 vaccines.

Throughout 2021-22, the ICMRA VPN focus was on 3 areas:

* facilitating internal and external communication of emerging safety signals
* collaborative action on Adverse Events of Special Interest (AESI) (including a simulation exercise)
* sharing information regarding AESI.

International collaboration in the VPN helped confirm several safety signals linked to COVID-19 vaccines and which regulatory actions were considered and implemented by regulatory agencies.

**Managing supply chains**

We have made improvements to medicine shortage data capabilities to enable more accurate forecasting of vulnerable medicine supply chains and have actively participated in the Global Regulators Working Group on Drug Shortages to exchange information on international medicine supply chains to manage and prevent important medicine shortages.

We have also worked across government, including with the Office of Supply Chain Resilience, (Department of Industry, Science and Resources) to share supply information and investigate potential vulnerabilities in Australia’s medicine supply chains.

Our support enabled continued access to appropriate treatments during a shortage. Between July 2021 and June 2022, we:

* published 4 Serious Scarcity Substitution Instruments allowing community pharmacists to substitute specific medicines for a medicine in shortage, without prior approval from the prescriber
* approved the import and supply of 144 overseas alternative medicines under section 19A of the *Therapeutic Goods Act 1989* to maintain continuity of supply of medicines in shortage
* worked with health professional peak bodies to develop clinical advice to manage important shortages.

We have made improvements to medicine shortage reporting and management, increasing transparency and implementing new management initiatives. Improvements were finalised to the mandatory shortage online reporting form requiring sponsors to provide more accurate information about anticipated, current and resolved shortages and discontinuations. We also introduced a new function on the medicine shortage reports database, allowing users to download a .csv file of all current or archived shortages to improve transparency and searchability.

* + 1. Goal 4. Strengthen regional regulatory capabilities for safer and effective therapeutics.

**Pacific Medicines Testing Program**

We participated in the Pacific Medicines Testing Program to assist participating Pacific Island Countries with access to Australian laboratory testing for therapeutic goods quality assurance.

2021 was the final year of the four-year Pacific Medicines Testing Program, which is funded by DFAT, with the program receiving a four-year extension until 2025 to continue its highly valued work with 13 Pacific countries. It now includes the ability to have COVID-19 products (such as face masks) and other medical devices tested.

The 2021-22 sample testing for the Pacific Medicines Testing Program received 26 samples from 9 participating countries.

**The Indo-Pacific Regulatory Strengthening Program**

The Program was launched in October 2018 and has the goal of increasing the availability of safe and effective medical products through improved regulatory practice and regional collaboration. The Program incorporates 7 countries: Thailand, Vietnam, Laos, Cambodia, Papua New Guinea (PNG), Myanmar and Indonesia.

In 2022 we worked closely with the PNG regulator on the evaluation of a dossier supporting the registration of chloramphenicol, an antibiotic that is used for the treatment of typhoid and cholera. We performed a full evaluation, developed a report template in line with the ASEAN Common Technical Document requirements and delivered a series of virtual workshops to discuss the evaluation process and areas of concern.

We worked with the Cambodian Department of Drugs and Food to establish clear Good Manufacturing Practice guidelines and templates. Two in‑country visits in 2022 allowed our team to work collaboratively with counterparts to draft an assessment checklist and associated guidance documents.

The online submission and workflow management software Integrated Regulatory Information Management System (IRIMS) has been successfully installed in Myanmar. IRIMS has been leveraged to triage and manage the submission queue. Support for select applications via videoconferences was made easier through the online registration system in between in-country missions.

The Food and Drug Department in Laos is concerned about management of a backlog of paper applications. We have been providing business process advice to assist with the implementation of strategies for backlog reduction and elimination, and to prevent a build‑up in the future.


|  |
| --- |
| **Case Study – Indo-Pacific Regulatory Strengthening Program** |
| In partnership with DFAT, we hosted the first face-to-face meeting of the Indo-Pacific Regulatory Strengthening Program since 2019. |
| The Steering Committee and Forum was held on 4–5 May 2022 in Singapore and brought together the regulatory agencies from Thailand, Indonesia, Papua New Guinea (PNG), Cambodia, Laos, Myanmar, and Vietnam. Also attending were national malaria control program representatives from Laos and PNG, regulators from Pakistan and partners such as the World Health Organisation, United States Pharmacopeia, the Centre for Regulatory Excellence and Asia Pacific Leaders for Malaria Elimination. |
|  |
| As well as providing an opportunity for collaborating regulators to highlight their recent challenges and successes, this year’s meeting covered 3 main themes: responding to the COVID-19 pandemic, strategies for malaria elimination, and regulatory reliance in action. |
| The Indonesian FDA gave an impressive presentation on how they have adapted their regulatory pathways to reduce COVID-19 vaccine evaluation time. |
| While COVID-19 has been all-consuming for the past 2 years, it is important not to neglect other infectious diseases prevalent in the region, such as malaria. Many partner countries are aiming to eliminate vivax malaria within the next 10-15 years, which is fast becoming a possibility with the approval and imminent roll out of the tafenoquine treatment, including the paediatric option recently approved by us. Dr Suchart from the Thai FDA also gave a presentation on how Thailand utilised technical support from us to approve tafenoquine in 2019, which allowed them to lead the ASEAN (Association of Southeast Asian Nations) joint assessment of tafenoquine with other countries in the region. |
|  |



**The Australian Expert Technical Assistance Program for Regional COVID-19 Vaccine Access – Regulatory Support and Safety Monitoring (AETEP-RSSM)**

The AETAP-RSSM was launched to support access to high quality, safe and effective COVID-19 vaccines, and aims to provide coordinated and holistic Australian policy and regulatory expertise to national COVID-19 immunisation programs in Southeast Asia and the Pacific. The AETAP‑RSSM commenced in April 2021 and incorporates 18 countries: Thailand, Vietnam, Laos, Cambodia, Papua New Guinea (PNG), Myanmar, Indonesia, Malaysia, the Philippines, Fiji, Samoa, Timor-Leste, Vanuatu, Tuvalu, Tonga, Kiribati, Solomon Islands and Nauru.

We supported Australian Government donations of COVID‑19 vaccines across the region, under a pledge to share 60 million doses. This involved the provision of batch testing results, testing protocols, GMP certificates and licences, pre-market evaluation reports and scientific advice. When requested, data related to ongoing safety monitoring was also shared.



Batch-specific documentation was provided for dozens of different batches, and technical assistance was provided to facilitate necessary regulatory approvals in Brunei, Indonesia, Vietnam, and PNG.

## Priority 4 – Education and compliance

### Industry compliance reforms

1. 1. 1. We monitored and enforced compliance, including the import, export, manufacture, supply, and advertising of therapeutic goods, imposing sanctions and penalties where necessary.

Monitoring and enforcement of compliance was actioned through analysis and review of complaints and reports received from the community, and advice from other regulators and agencies, including border and law enforcement agencies and state and territory regulators.

We prepared targeted education activities for wholesalers and suppliers within the vaping industry ahead of the changes to Nicotine Vaping Products in October 2021, and we developed specific educational materials in relation to the importation and supply of RATs (including parallel imports), to assist those new to the regulatory scheme to understand their obligations. Further education was required as many stakeholders had not previously had any retail need for obtaining and selling medical devices. For advertising-related compliance and enforcement outcomes and activities, please refer to our 2021-22 Advertising Compliance Annual Report.

We also monitored signals of non-compliance with Good Manufacturing Practice and used a risk-based approach to guide regulatory responses, investigating 235 signals of non-compliance for any impact of medicines supplied in Australia. We coordinated and managed recall actions for unsafe or defective therapeutic goods in the Australian market, as referenced earlier on page 12 of this report.

* + 1. We undertook a review of the Therapeutic Goods Advertising Code 2021, which took effect on 1 January 2022.

We updated web guidance to reflect the changes to the Code and will continue to improve this content going forward, based on stakeholder feedback. Multiple webinars to help guide advertisers through the Code were hosted throughout 2021-22, highlighting the changes, and explaining the compliance obligations for advertisers during the transition period.

We released several upgraded advertising compliance tools to improve the experience for stakeholders submitting enquiries, reports, and applications, as well as internal improvements to how we manage this information. The upgrades include a new Advertising Compliance Application (AC App), a case management system which replaced the Advertising Management System. Improvements have also been made to the advertising forms on our website, including reports of non-compliance, application for approval to use a restricted representation in advertising, and other advertising enquiries.

* + 1. We supported sponsors to understand their pharmacovigilance obligations and encouraged compliance through the Pharmacovigilance Inspection Program.

We operate the Pharmacovigilance Inspection Program to help sponsors maintain compliance with our requirements. In 2021-22 we evaluated Risk Management Plans Periodic Safety Update Reports, Summary Safety Reports for COVID-19 vaccines and products and operated the Pharmacovigilance Inspection Program to help sponsors maintain compliance with our requirements. Our pharmacovigilance inspectors conducted inspections, separate compliance investigations, issued infringement notices and reviewed enforceable undertakings[[25]](#footnote-26).

* + 1. We supported stakeholders in completing the transition to updated medicines labelling requirements.

A new version of the legislative instrument specifying advisory statements for certain medicines commenced on 1 January 2022. The Therapeutic Goods (Medicines Advisory Statements) Specification 2021 was made and follows several public consultations during 2021.

The Specification incorporates the Required Advisory Statements for Medicines Labels (RASML), which contains existing, and proposed, advisory label statements for relevant medicines. The Specification principally applies to over-the-counter medicines and registered complementary medicines and is designed to help ensure their safe and appropriate use. The updated RASML introduced new warning statement requirements for several medicines not previously covered by the RASML - those containing the active ingredients melatonin, menthol, methyl salicylate, mometasone and triptans. The Specification is intended to facilitate clarity in labelling requirements for sponsors.

* + 1. We provided additional information for healthcare professionals to clarify regulatory requirements and application processes for certain devices.

We provided a comprehensive range of information including guidance documents, publications, frequently asked questions, and other resources for healthcare professionals, sponsors, manufacturers, and consumers relating to the regulatory and administrative requirements for including a medical device on the Australian Register of Therapeutic Goods (ARTG). This guidance was updated as required and addressed topics of relevance to the sector, such as “Using face masks in healthcare settings” and “Custom-made medical devices”. In addition, we published instructions on our website for use of all COVID-19 RAT self-tests and required sponsors to have instructional videos and a helpline – to support consumers who purchased tests.

* + 1. We continued to develop new ways to provide support and education to small-to-medium enterprises (SME), start-ups, researchers, and those unfamiliar with regulation through SME Assist.

SME Assist offers SMEs, researchers, start-ups and those unfamiliar with therapeutic goods regulation guidance to understand their regulatory and legislative obligations. We do this through workshops, webinars, interactive decision tools and podcasts. ​​​​​​​​​​​​​​We published our first series of podcasts on 'Navigating Therapeutic Goods Regulation' which have resulted in hundreds of downloads. To effectively action and manage almost 60,000 enquiries during 2021-22 (an increase of 55% from enquiries pre-COVID-19), we introduced a new enquiry management system that allows our Customer Service operators to quickly interact with our Subject Matter Experts to provide consistent advice to external stakeholders.

* + 1. To support patient safety, we managed restrictions to the advertising and supply of autologous cell and tissue therapies.

In July 2018, changes to the regulation of autologous hematopoietic cell transplantation (HCT) products in Australia prohibited consumer advertising of autologous human cell and tissue products and regulated the supply of autologous products that involve significant product processing.

During 2021-22 we received 7 reports alleging unlawful advertising of HCT therapies which resulted in 4 cases for further investigation. We removed over 100 products from a digital platform where the advertising referenced plant extracts and claimed they had properties similar to “stem cells”. We investigated one entity for this type of advertising and achieved voluntary compliance. Consistent with our Import, Advertising and Supply Compliance Priorities 2021-22, we are focusing on alleged unlawful advertisements which make claims about human cell and tissue products that relate to a serious disease or condition and are not substantiated by robust evidence.

### Public safety education

* 1. 1. We improved understanding of how therapeutic goods regulation is relevant to consumers, health professionals, and industry through the development of regulatory education materials, including tailored content resources, videos, infographics, webinars, podcasts, and other tools.

In 2021-22 we focused on significant stakeholder consultation, input, and education, with over 70 webinars and workshops covering a range of topics, including our extensive reform agenda and the commencement of new regulatory requirements for Software as a Medical Device and Personalised Medical Devices, along with patient information materials and up-classification of certain devices.

All the content we produce for social media aims to connect our work to audience needs. For example, our Vaccine Safety explainer video (which reached 95,000 people) educated viewers about using and understanding trusted sources of information about COVID-19 vaccine safety. We also ran an advertising campaign regarding medicinal cannabis access and regulation. The campaign targeted both consumers and health professionals and aimed to raise awareness of the options available regarding access to these products.

* + 1. We educated consumers about counterfeit therapeutic goods through the publication of safety alerts and other education materials.

We provide information to consumers regarding counterfeit therapeutic goods through our publication safety alerts on our website.

In 2021-22 the alerts included:

* counterfeit Nitrile gloves
* counterfeit Somatropin Human Growth Hormone vials
* erectile dysfunction treatment claiming to contain herbal ingredients but also containing the undisclosed ingredient sildenafil
* hemp oil supplement that contained undisclosed amounts of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)
* a warning for consumers, advertisers, importers, and suppliers regarding counterfeit NVPs.
  + 1. We provided awareness-raising activities to support adverse event reporting by consumers and health professionals, particularly for COVID-19 vaccines.

As part of a wider Department of Health communications program, we raised awareness of adverse event reporting channels and provided greater availability of services. This includes developing resources to educate the public about reporting an adverse event and increasing the operating hours of the NPS MedicineWise Adverse Medicine Events Line. There has been an increase in the number of vaccine adverse event reports received since before the COVID-19 vaccine rollout, particularly from consumers.

We educated consumers on the regulatory changes to NVPs that took effect from 1 October 2021. Following the 1 October 2021 scheduling reforms for nicotine, it is necessary for consumers to have a prescription from an Australian doctor to import or obtain NVPs. We undertook extensive work to educate all stakeholders about the reforms.

To help increase consumer awareness and understanding of the NVP changes, we launched an information and education campaign, targeted across various social media and search engines, along with General Practitioner practices and pharmacies. We worked with a range of stakeholders to tailor information to targeted audiences, including carers and those they care for, indigenous audiences and those from culturally and linguistically diverse backgrounds.

We also released fact sheets and a new video. The video was shared across our social media channels and is part of our national information and education campaign to ensure consumers and health professionals are aware of the new nicotine vaping requirements. One of the goals of the campaign is to encourage consumers to visit their GP to discuss quitting smoking. The Nicotine Vaping Products hub on our website contains further information and resources regarding the regulation of NVP.

**Case Study – Adverse event information for COVID-19 vaccines**

We developed a short video to help Australians understand the different adverse event information that we publish regarding the COVID-19 vaccines. The video highlights the difference between the unassessed reports of possible side effects provided on the Database of Adverse Events Notifications (DAEN) from the carefully assessed information we provide to the public in the COVID-19 vaccine safety report.

The video was an in-house production. It has been promoted on our social media channels and has been used in response to enquiries and misinformation received through these channels, as deemed appropriate.



* + 1. We continued to undertake and publish the outcomes of listed medicine compliance reviews and educate consumers about the compliance review process.

During the reporting period we published the results of 78 listed medicine compliance reviews. The database provides consumers with compliance information relating to listed medicines that we have reviewed.

### Access to information for Industry and Consumers

* 1. 1. We provided exhibition booths at events to assist with providing up-to-date information on regulatory changes, and emerging issues and trends.

In 2021-22 we provided opportunities for industry and consumers to hear from and speak with us as many conferences and events. We presented and participated at seminars, exhibitions and conferences including:

* SME Assist Workshop – Supplying Personal Protective Equipment (July 2021)
* SME Assist Workshop – Meeting Your Obligations (August 2021)
* SME Assist Workshop - Supplying Medicinal Cannabis in Australia (October 2021)
* SME Assist Workshop - Flinders University (March 2022)
* SME Assist Workshop - Bridgetech (April 2022)
* Association of Regulatory and Clinical Scientists (ARCS) 2022 – Exhibition Booth (May 2022)
* AusMedtech – Exhibition Booth (May 2022)
* General Practice Conference & Exhibition – exhibition booth (May 2022).

We attended the ARCS Annual Conference in Sydney in May 2022 which is an example of our commitment to engage with our stakeholders. The conference brought together industry professionals, consumers, patients, practitioners, researchers, and academia to unite and educate. The Deputy Secretary provided a keynote address to the conference on 'How to improve patient outcomes through regulation in the digital world', while other staff updated attendees on the regulatory environment in Australia. We also had an exhibition booth at the conference.

Also, the Deputy Secretary and other senior executives of the TGA spoke at a wide range of other stakeholder events to discuss regulatory changes and emerging issues and trends. The Deputy Secretary spoke at over 50 national and international forums in 2021-22. Notable domestic ones included:

* Fortnightly/monthly COVID vaccine, treatment and testing updates for health professionals (July 2021- June 2022)
* Medicines repurposing forums (July 2021 and May 2022)
* Australian Industry Group (September 2021)
* Pharmacy Guild (July 2021 and March 2022)
* Theranostics national conference (September 2021)
* Deakin University/Geelong centre for Emerging Infectious diseases (November 2021)
* Medical Technology Association of Australia (November 2021)
* Royal Australasian College of Physicians (November 2021)
* Consumer Healthcare Products Australia (November 2021)
* High Blood Pressure Research Council (December 2021)
* Complementary Medicines Australia (December 2021)
* A-Cannabis (March 2022)
* Pathology Technology Australia (April 2022)
* Community Group presentations on COVID (May 2022)
* AusMedtech (May 2022)
* Generic Biosimilar Medicines Association (May 2022)
* National cannabis patient and healthcare professional conference (May 2022)
* Direct Selling Australia (May 2022).
  + 1. We maintained our website to ensure that it is accessible, easy to navigate, accurate, and meets the needs of industry, health professionals and the general public, while working towards the development of a new website which was implemented in 2022-23.

We maintained our website to ensure that it is accessible, easy to navigate, accurate, and meets the needs of industry, health professionals, and the public, while working towards the development of a new website which was implemented in 2022-23.

|  |
| --- |
| **Case Study – TGA Website Redevelopment Project**  Through the TGA Website Redevelopment Project, our website was rebuilt to be a more modern portal for accessing information.  The project was informed by research which has shown our previous website:   * did not meet user or business needs * acted as a barrier to communication, education, and compliance * had content that is not understood by our users * prevented users from completing common tasks.   The new website went live on 30 August 2022. This is just the first part, delivering:   * a cohesive experience and consistent user interface with familiar interaction and search patterns * an improved and consolidated experience for databases and feed * rewritten content that meets standards for Australian Government websites.   In the coming years, our new website will be integral to many of our transformation projects. In 2021-22, we published more than 1,900updates (many related to COVID-19) on our website. |

* + 1. We expanded our education capability by partnering to enhance our engagement with consumers, health professionals, and industry stakeholders.

We worked with ANDHealth to deliver education activities about software medical devices through the ANDHealth and TGA partnership, with the first webinar held on 7 September 2021.

We also partnered with several organisations (the Federation of Ethnic Communities’ Councils of Australia (FECCA), the National Aboriginal Community Controlled Health Organisation (NACCHO), Ninti One Ltd, and Carers Australia) to deliver an 8-week campaign informing consumers of the changes to nicotine vaping laws. These partnerships were crucial in targeting mainstream, Indigenous and Culturally and Linguistically Diverse (CALD) audiences. A total of 28 pieces of content were developed for various platforms, reaching over 20 million people, and generating over 100,000 clicks through to the web content.

* + 1. We informed and educated consumers, health professionals, and stakeholders on regulatory changes in priority areas through targeted digital communication campaigns and activities.

Throughout 2021-22 we delivered seven paid public education campaigns:

* NVPs – 1 October to 13 November 2021
* get vaccine safety information you can trust – 15 December 2021 to 15 January 2022
* changes to the application process for unapproved medicinal cannabis products – 17 December 2021 – 1 February 2022
* rapid antigen self-tests: advice on using saliva RATs – 7 February to 7 March 2022
* COVID-19 therapeutics – 4 March to 28 March 2022
* rapid antigen self-tests: buying compliant RATs – 25 March to 22 April 2022
* pathways to access unapproved medicinal cannabis products – 16 June to 30 June 2022.

The campaigns performed extremely well, reaching on average almost 1.7 million people per campaign, and achieving more than 3.6 million impressions per campaign (the number of times the content was displayed). A goal for the campaigns was to raise awareness among consumers and health professionals of priority education topics. This was measured through the CPR achieved – the Cost Per 1,000 people Reached. This demonstrates that the content was relevant and engaging to the target audiences. We also managed the unpaid activity on our social media accounts, including Facebook, Twitter, LinkedIn, Instagram, and YouTube, to maximise audience reach and ensure messages are distributed in channels used by consumers, health professionals, and other stakeholders.

* + 1. We managed social media accounts, including Facebook, Twitter, LinkedIn, Instagram, and YouTube to maximise audience reach and ensure messages are distributed in channels used by consumers, health professionals, and other stakeholders.

We reached almost 20 million people through our series of 7 paid advertising campaigns on social media. Overall, our following recorded an increase in followers during the reporting period: Facebook +52%, Twitter +74%, Instagram +446% and LinkedIn +49%. Proactive campaigns contributed to these increases and helped ensure new audiences will be exposed to our posts in the future. We also produced and published over 100 videos (including recorded webinars).

# Appendices

The appendices provide detailed statistical information on our performance during 2021-22.

1. Prescription Medicines

Applications to register new or vary existing prescription medicines are accompanied by supportive scientific data and evaluated, with timeframes underpinned by legislation and/or associated business rules.

The framework for prescription medicines includes the following categories which are subject to legislated and/or target timeframes:

|  |  |  |
| --- | --- | --- |
| Application category | Description | Timeframe in working days |
| Category 1 | An application to register a new prescription medicine (other than an additional trade name) or to make a variation to an existing medicine that involves the evaluation of clinical, pre‑clinical or bio-equivalence data. For example, new chemical entities, extensions of indication and new routes of administration. | Legislated timeframe: 40 working days for notification of whether the application has passed preliminary assessment and 255 working days for the completion of the evaluation and notification of the decision.  For the priority review pathway, the target timeframe is 150 working days. |
| Comparable Overseas Regulator (COR) report-based process | An application accompanied by an un-redacted assessment report package from a comparable overseas regulator. | Legislated timeframe: 40 working days for notification of whether the application has passed preliminary assessment. The timeframe for completion of the evaluation and notification of the decision depends on the COR pathway:   * COR-Aa: 120 working days * COR-Ba: 175 working days |
| Category 3 | An application to register or to vary the registration of a prescription medicine where the application does not require the support of clinical, pre‑clinical or bio-equivalence data.  For example, broader changes to the product specifications, manufacturing and labelling or a change in trade name. | Legislated timeframe: 45 working days to notify the applicant of the decision. |

a Under COR-A, the TGA regulatory decision will be based on a critical review of the COR assessment reports and an evaluation of the Australian label, Product Information (PI) and where required, the Risk Management Plan (RMP). Under the COR-B approach, the TGA regulatory decision will still be mostly based on a critical review of the COR assessment reports, and where required, the RMP.

| Application category | Description | Timeframe in working days |
| --- | --- | --- |
| Correction to, or completion of, a Register entry | An application to vary the registration of a prescription medicine to correct or complete information that was inadvertently recorded incorrectly or omitted from the Register entry.  For example, errors to product information, or quality-related documentation. | No legislated timeframe: TGA processes as soon as possible. |
| Safety-related request | An application to vary the registration of a prescription medicine to either:   * reduce the patient population that can receive the medicine or * add a warning or precaution. | No legislated timeframe: TGA processes as soon as possible. |
| Notification request to vary an ARTG entry | An application to vary the registration of a prescription medicine, where the application has been determined to pose a very low risk under certain conditions.  For example, the removal of a redundant manufacture site. | No legislated timeframe: automatic approval on submission of e-form and full payment of fee. |
| Self-assessable request | An application to register or to vary the registration of a prescription medicine where the application:   * does not require the support of clinical, pre‑clinical or bio-equivalence data and * where no data are necessary or where the data can be self-assessed by the applicant.   For example, certain changes to the pack size or approved product label. | Legislated timeframe: 45 working days for notification of acceptance or rejection of an application, completion of evaluation and notification of the decision. |
| Additional trade name | An application for an additional trade name for a registered prescription medicine. | Legislated timeframe: 45 working days. |

* 1. Submission outcomes

Table 1 Number of completed prescription medicine submissions by type and outcome for July 2021 to June 2022

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Number** | | | |
| **Application Type** | **Approved** | **Withdrawn** | **Rejected** | **Total (% Approved)** |
| Category 1 | | | | |
| A: New chemical entity/New biological entity/Biosimilar a | 47 | 4 | 0 | 51 (92%) |
| B: New fixed-dose combination | 3 | 0 | 0 | 3 (100%) |
| C: Extension of indication | 56 | 5 | 0 | 61 (92%) |
| D: New generic medicine | 82 | 20 | 0 | 102 (80%) |
| F: Major variation | 40 | 2 | 0 | 42 (95%) |
| G: Minor variation b | 3 | 0 | 0 | 3 (100%) |
| H: Minor variation c | 12 | 0 | 0 | 12 (100%) |
| J: Changes to Product Information | 95 | 1 | 0 | 97 (98%) |
| S: Provisional registration to full registration | 4 | 0 | 0 | 4 (100%) |
| T: Provisional registration extension [T] | 3 | 0 | 0 | 4 (100%) |
| Comparable Overseas Regulator (COR) – A | | | | |
| A: New chemical entity/New biological entity/Biosimilar | 2 | 0 | 0 | 2 (100%) |
| C: Extension of indication | 2 | 0 | 0 | 2 (100%) |
| Comparable Overseas Regulator (COR) – B | | | | |
| A: New chemical entity/New biological entity/Biosimilar | 5 | 0 | 0 | 5 (100%) |
| B: New fixed-dose combination | 1 | 0 | 0 | 1 (100%) |
| C: Extension of indication | 1 | 0 | 0 | 1 (100%) |
| D: New generic medicine | 4 | 0 | 0 | 4 (100%) |
| F: Major variation | 1 | 0 | 0 | 1 (100%) |
| Minor Variations | | | | |
| Category 3 | | | | |
| G: Minor variation b | 61 | 7 | 0 | 68 (90%) |
| H: Minor variation c | 1,483 | 32 | 0 | 1,515 (98%) |
| Correction [9D(1)] | 233 | 9 | 0 | 242 (96%) |
| Additional trade name [ATN] | 43 | 0 | 0 | 43 (100%) |
| Extension of Indications - Generic | 24 | 1 | 0 | 25 (96%) |
| Internal Review | 3 | 0 | 0 | 3 (100%) |
| Minor editorial change [MEC] | 152 | 6 | 0 | 158 (96%) |
| Notification | 1,621 | 16 | 0 | 1,637 (99%) |
| Self-assessable request [SAR] | 634 | 20 | 1 | 0 (97%) |
| Safety-related request [SRR] | 831 | 14 | 0 | 845 (98%) |
| Total | 5,446 | 137 | 1 | 5,884 (98%) |

a Includes submissions processed via the priority review.  
b The type G minor variations differ from type H minor variations in that they result in a new ARTG entry.  
c The minor variations (type H) refer to applications to change the formulation, composition or design specification or the container for the goods or any other attribute that results in the goods being separate and distinct. These applications are typically ‘Category 3’ changes unless the supporting scientific package contains non-clinical or clinical data in which case the application is a ‘Category 1’ application.

In accordance with the legislation, registered medicines must comply with numerous standards at the time they are registered and throughout their lifecycle. Following an appropriate application and review of the scientific data and safety considerations, approval may be sought to supply a product when it does not meet a particular standard.

Table 2 Number of other prescription medicine applications

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
| **July to June** | |
| Consent to supply/import/export when not conforming to a  standard [S.14 and S.14A] | **Number (% of Total)** | |
| Approved | 170 (100%) | 94 (99%) |
| Rejected | 0 (0%) | 1 (1%) |
| Total (excluding withdrawals) | 170 (100%) | 95 (100%) |

* 1. Approval times

Table 3 Prescription medicine application approval time for July 2021 to June 2022

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| hac |  | |  | |  | Approval time (TGA working days) | | |
| **Application type** | | **Submissions Approved** | | **Legislated timeframe** | | **Mean** | **Median** | **Range** |
| Category 1 | | | | | | | | |
| A: New chemical entity/New biological entity/Biosimilar a | | 44 | | 255 | | 174 | 191 | 23-151 |
| B: New fixed-dose combination | | 3 | | 255 | | 198 | 196 | 193-206 |
| C: Extension of indication b | | 53 | | 255 | | 184 | 198 | 39-253 |
| D: New generic medicine | | 82 | | 255 | | 140 | 139 | 81-190 |
| F: Major variation | | 40 | | 255 | | 159 | 170 | 8-227 |
| G: Minor variation | | 3 | | 255 | | 185 | 184 | 161-209 |
| H: Minor variation | | 12 | | 255 | | 178 | 186 | 58-236 |
| J: Changes to Product Information requiring the evaluation of data | | 95 | | 255 | | 155 | 183 | 18-243 |
| S: Provisional registration to full registration | | 2 | | N/A | | 217 | 217 | 179-254 |
| T: Provisional registration extension | | 3 | | N/A | | 271 | 55 | 38-121 |
| Comparable Overseas Regulator (COR-A) | | | | | | | | |
| A: New chemical entity/New biological entity/Biosimilar a | | 2 | | 120 | | 115 | 115 | 112-117 |
| C: Extension of indication b | | 2 | | 120 | | 105 | 105 | 91-118 |
| Comparable Overseas Regulator (COR-B) | | | | | | | | |
| A: New chemical entity/New biological entity/Biosimilar | | 5 | | 175 | | 145 | 141 | 122-166 |
| B: New fixed-dose combination | | 1 | | 175 | | 160 | 160 | 160-160 |
| C: Extension of indication | | 1 | | 175 | | 183 | 183 | 183-183 |
| D: New generic medicine | | 4 | | 175 | | 117 | 110 | 105-145 |
| F: Major variation | | 1 | | 175 | | 174 | 174 | 174-174 |

a Application type A figures do not include 3 submissions processed via the priority review pathway.

b Application type C figures do not include 3 submissions processed via the priority review pathway.

Table 4 Prescription medicine median approval time comparisons between 2020-21 and 2021-22

|  | |  | **Median approval time (TGA working days)** | |
| --- | --- | --- | --- | --- |
| **Application type** | **Legislated timeframe** | | **2020-21** | **2021-22**  **(% Change)** |
| Category 1 | | | | |
| A: New chemical entity/New biological entity/Biosimilar a | 255 | | 195 | 191 (▼2%) |
| B: New fixed-dose combination | 255 | | 197 | 196 (▼1%) |
| C: Extension of indication b | 255 | | 194 | 198 (▲2%) |
| D: New generic medicine | 255 | | 148 | 139 (▼6%) |
| F: Major variation | 255 | | 170 | 170 (▼6%) |
| G: Minor variation | 255 | | 139 | 184(▲35%) |
| H: Minor variation | 255 | | 137 | 186 (▲35%) |
| J: Changes to Product Information requiring the evaluation of data | 255 | | 111 | 183 (▲66%) |
| Comparable Overseas Regulator (COR) – A | | | | |
| A: New chemical entity/New biological entity/Biosimilar | 120 | | 167 | 115 (▼31%) |
| C: Extension of indication | 120 | | 97 | 105 (▲8%) |
| Comparable Overseas Regulator (COR) – B | | | | |
| A: New chemical entity/New biological entity/Biosimilar | 175 | | 157 | 141 (▼10%) |
| C: Extension of indication | 175 | | 173 | 183 (▲6%) |
| D: New generic medicine | 175 | | 145 | 110 (▼24%) |
| Minor Variations | | | | |
| Category 3 | | | | |
| G: Minor variation c | 45 | | 38 | 39 (▲3%) |
| H: Minor variation d | 45 | | 35 | 35 (▼0%) |
| Additional trade name [ATN] | 45 | | 18 | 35 (▲94%) |
| Extension of Indications - Generic | 45 | | 36 | 40 (▲10%) |
| Safety-related request [SRR] | N/A | | 33 | 37 (▲12%) |
| Self-assessable request [SAR] | 45 | | 36 | 32 (▼11%) |
| Minor editorial change [MEC] | 45 | | 32 | 33 (▲3%) |
| Correction [9D(1)] | N/A | | 173 | 42 (▼74%) |

a Application type A figures do not include submissions processed via the priority review pathway.

b Application type C figures do not include submissions processed via the priority review pathway.

c The type G minor variations differ from type H minor variations in that they result in a new ARTG entry.

d The minor variations (type H) refer to applications to change the formulation, composition or design specification or the container for the goods or any other attribute that results in the goods being separate and distinct. These applications are typically ‘Category 3’ changes unless the supporting scientific package contains non-clinical or clinical data in which case the application is a ‘Category 1’ application.

Figure 1 Mean approval times (TGA working days) for submissions a by pathway 2020-21 and 2021-22

Figure 2 Median approval times (TGA working days) for submissions a by pathway 2020-21 and 2021-22

a For new chemical entities, new combinations, extension of indications, new generic medicines and major variations. During these periods, volumes of submission approvals for 2020-21 and 2021-22 were: standard - 223 and 202, priority review - 6 and 11, provisional approval - 10 and 6, COR-A - 2 and 0 and COR-B - 8 and 9, respectively.

* 1. Orphan drug designations

The objective of the orphan drug program is to provide an incentive to sponsors to bring medicines for a small population to market and make medicines available to Australian patients who may not otherwise be able to access them. The program incentive is a 100% waiver of TGA fees for application and registration. Designation is a formal process that allows us to make a decision regarding whether a medicine is eligible for orphan drug designation. This precedes the registration application. The eligibility criteria aim is to focus the program on the greatest unmet need. A prescription medicine must have a valid orphan drug designation at the time of application to be eligible for a waiver of application and evaluation fees.

Table 5 Number of orphan drug registrations

Orphan drug registrations and approval times quoted in Table 6 are also included in the total number of applications reported in each respective application category in the tables and figures below.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 2020-21 | | 2021-22 | |
| **July to June** | | | |
| Application Type | Number Approved  (% of Total) | Median approval time (TGA working days) | Number Approved  (% of Total) | Median approval time (TGA working days) |
| A: New chemical entity/New biological entity/Biosimilar | 15 (75%) | 170 | 16 (70%) | 163 |
| C: Extension of indications | 2 (10%) | 111 | 6 (26%) | 196 |
| F: Major variation | 3 (15%) | 180 | 1 (4%) | 174 |
| Total | 20 (100%) | 172 | 23 (100%) | 174 |

* 1. Priority review pathway

The priority review pathway supports patient access to vital and lifesaving prescription medicines months earlier than through the standard pathway. Priority review involves the same amount and type of evidence as the standard review process. The same standards for quality, safety and efficacy apply as under the standard process. The flexible approach we take on priority applications is much more resource intensive than the standard pathway. The pathway is reserved only for medicines that represent a major therapeutic advance. The determination process is used to assess whether a medicine is eligible for the priority pathway but does not necessarily mean that the medicine will be approved after evaluation and registered on the ARTG.

Table 6 Number of medicines approved through the priority review pathway a

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 2020-21 | | 2021-22 | |
|  | **July to June** | | | |
| Application Type | Number Approved (% of Total) | Median approval time (TGA working days) | Number Approved (% of Total) | Median approval time (TGA working days) |
| A: New chemical entity/New biological entity/Biosimilar | 3 (36%) | 123 | 3 (50%) | 120 |
| C: Extension of indications | 7 (64%) | 141 | 3 (50%) | 147 |
| Total | 10 (100%) | 133 | 6 (100%) | 144 |

a The target timeframe for the priority review pathway is 150 working days.

* 1. Provisional approval pathway

The provisional approval pathway supports patient access to vital and lifesaving prescription medicines earlier than through the standard pathway. Time limited approval through the provisional pathway is based on the evaluation of preliminary clinical data where there is the potential for a substantial benefit to Australian patients. Knowledge of the risks and benefits of these medicines is less certain than for other approved prescription medicines. Provisional approval is granted for promising new medicines where we assess that the benefit of early availability of the medicine outweighs the risk inherent in the fact that additional data are still required.

A prescription medicine must have a valid provisional determination before it can be evaluated for registration under the provisional approval pathway. The determination process is used to assess whether a medicine is eligible for the provisional pathway but does not necessarily mean that the medicine will be approved after evaluation and provisionally registered on the ARTG.

Table 7 Number of provisional determinations granted

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 2020-21 | | 2021-22 | |
| **July to June** | | | |
| Application Type | Number Approved | Total Applications | Number Approved | Total Applications |
| Provisional Determination | 18 | 19 | 29 | 29 |

Table 8 Provisional approval registrations

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 2020-21 | | 2021-22 | |
|  | **July-June** | | | |
|  | Number Approved  (% of total) | Median approval time (TGA working days) | Number Approved  (% of total) | Median approval time (TGA working days) |
| Application type | |  |  | |
| A: New chemical entity/New biological entity/Fixed dose combination | 5 (83%) | 136 | 13 (46%) | 88 |
| C: Extension of indications | 0 (0%) | N/A | 10 (36%) | 54 |
| F: Major variation | 0 (0%) | N/A | 4 (14%) | 23 |
| T: Provisional registration extension | 1 (17%) | 37 | 1 (4%) | 121 |
| **Total** | 6 (100%) | 96 | 28 (100%) | 68 |

1. Over-the-Counter Medicines

Over-the-Counter (OTC) medicine applications are categorised as new medicine (N) or change (C) applications and are further categorised by risk (N1 and C1 are low risk, N5 and C4 are highest risk). The OTC application categorisation framework outlined on the following page defines the different OTC medicine application levels and the key application criteria.

Table 9 Categorisation of OTC medicine applications

|  |  |  |
| --- | --- | --- |
| Application category | Definition | Timeframe in days |
| N1 | An application submitted as a ‘clone’. | 45 working days |
| N2 | An application which complies with an OTC medicine monograph. | 55 working days |
| N3 | New application for a ‘generic’ medicine other than those ‘generic’ applications in levels N1, N2 or N4. | 150 working days |
| N4 | An application for a ‘generic’ medicine where the medicine: requires supporting safety and/or efficacy (clinical/toxicological) data or a justification for not providing such data; and/or requires a higher level of assessment due to the umbrella branding segment of the product name; and/or has not been previously registered as an OTC medicine following down-scheduling. | 170 working days |
| N5 | An application for a new product that is an extension to a ‘generic category’ product or an application for a product containing a new chemical entity as an active ingredient. | 210 working days |
| CN | 'Notification' changes, where their implementation would not impact the quality, safety or efficacy of a medicine. Includes quality and non-quality changes classified as 'negligible risk'. | N/A  (Automated validation and approval) |
| C1 | Quality and non-quality changes classified as ‘negligible risk’. | 20 working days |
| C2 | Quality and non-quality changes classified as ‘low risk’ – no safety and/or efficacy data required; quality data may be required. | 64 working days |
| C3 | Quality and non-quality changes classified as ‘low risk’ – safety and/or efficacy data required unless justified; quality data may be required. Umbrella branding segment of new name requires a higher level of assessment. | 120 working days |
| C4 | Non-quality changes classified as ‘moderate risk’ – safety and/or efficacy data required unless justified. | 170 working days |
| B1 | Request for advice in relation to a registered OTC medicine for the purpose of listing the medicine as a pharmaceutical benefit that does not contain clinical data. | 20 working days |
| B3 | Request for advice in relation to a registered OTC medicine for the purpose of listing the medicine as a pharmaceutical benefit that contains clinical data or a justification as to why such data is not needed. | 120 working days |
| Requests for consent under section 14/14A of the Act | Request for consent by the Secretary under sections 14 and 14A of the Act to the import, export or supply of therapeutic goods that do not comply with an applicable standard. | N/A |

* 1. Approval times

We aim to have 80% of applications completed within target timeframes. The following target timeframes apply to OTC medicine applications:

Table 10 Median approval time for OTC medicine applications

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| New medicine applications (days) |  |  |
| N1 | 38 | 36 |
| N2 | 37 | 28 |
| N3 | 90 | 120 |
| N4 | 126 | 163 |
| N5 | 223 | 289 |
| Change applications (days) |  |  |
| C1 | 7 | 14 |
| C2 | 40 | 24 |
| C3 | 88 | 50 |
| C4 | 318 | 0 |

Table 11 OTC medicine approval time against target time by application category July 2021 to June 2022

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Application type | Number completed (% of Total) | Range | Mean | Median | % within target |
| New medicines | | | | | |
| N1 | 71 (36%) | 0-127 | 38 | 36 | 65 |
| N2 | 9 (5%) | 2-50 | 26 | 28 | 100 |
| N3 | 62 (32%) | 26-206 | 119 | 120 | 74 |
| N4 | 43 (22%) | 63-295 | 174 | 163 | 56 |
| N5 | 11 (6%) | 134-311 | 267 | 289 | 18 |
| **Total** | 196 (100%) |  |  |  |  |
| Change applications | | | | | |
| C1 | 278 (46%) | 0-86 | 15 | 14 | 78 |
| C2 | 300 (50%) | 0-193 | 32 | 24 | 87 |
| C3 | 20 (3%) | 1-141 | 58 | 50 | 95 |
| C4 | 0 (0%) | 0 | 0 | 0 | 0 |
| **Total** | 598 (100%) |  |  |  |  |

* 1. Applications

#### New OTC medicine applications

Table 12 Applications received for new OTC medicines and changes to existing medicines

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| New medicine applications | | |
| N1 | 107 (45%) | 90 (46%) |
| N2 | 23 (10%) | 21 (11%) |
| N3 | 71 (30%) | 57 (29%) |
| N4 | 30 (13%) | 25 (13%) |
| N5 | 5 (2%) | 3 (2%) |
| Total | 236 (100%) | 196 (100%) |
| Change applications | | |
| CN | 128 (17%) | 184 (23%) |
| C1 | 234 (32%) | 315 (39%) |
| C2 | 349 (48%) | 293 (36%) |
| C3 | 19 (3%) | 11 (1%) |
| C4 | 1 (0.1%) | 0 (0%) |
| Total | 731 (100%) | 803 (100%) |

#### Completed applications

Table 13 New OTC medicine applications completed and outcomes

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| N1 | | |
| Approved | 101 (94%) | 71 (95%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 6 (6%) | 4 (5%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 107 (100%) | 75 (100%) |
| N2 | | |
| Approved | 19 (83%) | 9 (100%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 4 (17%) | 0 (0%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 23 (100%) | 9 (100%) |
| N3 | | |
| Approved | 49 (73%) | 62 (97%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 13 (19%) | 2 (3%) |
| Returned/failed screening | 5 (7%) | 0 (0%) |
| Total | 67 (100%) | 64 (100%) |
| N4 | | |
| Approved | 20 (83%) | 41 (89%) |
| Rejected | 0 (0%) | 2 (4%) |
| Withdrawn by sponsor | 2 (8%) | 2 (4%) |
| Returned/failed screening | 2 (8%) | 1 (2%) |
| Total | 24 (100%) | 46 (100%) |
| N5 | | |
| Approved | 8 (100%) | 10 (59%) |
| Rejected | 0 (0%) | 1 (6%) |
| Withdrawn by sponsor | 0 (0%) | 3 (18%) |
| Returned/failed screening | 0 (0%) | 3 (18%) |
| Total | 8 (100%) | 17 (100%) |

Table 14 OTC change applications completed and outcomes

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| C1 | | |
| Approved | 212 (95%) | 278 (98%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 12 (4%) | 6 (2%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 224 (100%) | 284 (100%) |
| C2 | | |
| Approved | 350 (98%) | 300 (93%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 7 (2%) | 21 (7%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 357 (100%) | 321 (100%) |
| C3 | | |
| Approved | 4 (80%) | 20 (95%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 1 (20%) | 1 (5%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 5 (100%) | 21 (100%) |
| C4 | | |
| Approved | 6 (86%) | 0 (0%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn by sponsor | 1 (14%) | 1 (100%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 7 (100%) | 1 (100%) |

#### Other applications

Other application types that we process include requests for advice for the purpose of listing a medicine as a pharmaceutical benefit. In accordance with the legislation, registered goods must comply with numerous standards at the time they are registered and throughout their lifecycle. Following an appropriate application and review of the scientific data and safety considerations, we may grant an exemption from a particular standard for a product.

Table 15 Number of other OTC medicine applications

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
| **July to June** | |
|  | **Number (% of Total)** | |
| Requests for advice for the purpose of listing a medicine as a pharmaceutical benefit | | |
| Total | 0 | 0 |
| Requests for consent under section 14/14A of the Act to import, export or supply therapeutic  goods not complying with an applicable standard | | |
| Approved a | 81 (99%) | 13 (100%) |
| Rejected | 1 (1%) | 0 (0%) |
| Total | 82 (100%) | 13 (100%) |

a This includes 49 requests for consent to supply products that do not comply with TGO92 only that was established as a temporary expedited process for sponsors adversely impacted by the COVID-19 pandemic.

1. Registered Complementary Medicines

Registered complementary medicines are considered to be of relatively higher risk than listed medicines based on their ingredients or the indications for the medicine. These medicines are fully evaluated by us for safety, efficacy, performance, and quality prior to being registered on the ARTG.

Table 16 Registered complementary medicine applications by outcome

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| New medicines | | |
| Approved | 9 (64%) | 5 (50%) |
| Rejected | 1 (7%) | 2 (20%) |
| Withdrawn | 4 (29) | 3 (30%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total | 14 (100%) | 10 (100%) |
| Variations | | |
| Approved | 71 (100%) | 21 (75%) |
| Rejected | 0 (0%) | 1 (4%) |
| Withdrawn | 0 (0%) | 6 (21%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total variations completed | 71 (100%) | 28 (100%) |
| Application for consent under section 14/14A of the Act to import, export or supply therapeutic  goods not complying with an applicable standard | | |
| Approved | 4 (100%) | 2 (67%) |
| Rejected | 0 (0%) | 0 (0%) |
| Withdrawn | 0 (0%) | 1 (33%) |
| Total | 4 (100%) | 3 (100%) |

2. Assessed Listed Medicines

Assessed listed medicines are considered to be of slightly higher risk than listed medicines based on their indications, but not as high risk as registered medicines. Because assessed listed medicines carry intermediate risk indications, they are fully evaluated by us for efficacy before listing in the ARTG.

Assessed listed medicine applications are categorised as new medicine (‘L(A)’) or change (C) applications. The application levels are outlined in Table 19.

Table 17 Categorisation of assessed listed medicine applications

|  |  |  |
| --- | --- | --- |
| Application category | Definition | Evaluation timeframe  (legislated) |
| L(A)1 | Medicines that are identical to an existing assessed listed medicine other than permitted differences, such as its name, colour, printing ink, flavour and/or fragrance. | 45 working days |
| L(A)2 | Generic medicines or medicines where a Comparable Overseas Body (COB) has demonstrated their efficacy. | 60 working days |
| L(A)3 | Medicines that are not covered by L(A)1 or L(A)2; and require an independent evaluation of their efficacy; or for an existing assessed listed medicine, contain a different active ingredient, indication, dosage form, strength, or excipient. | 150 working days |
| L(A)CN | 'Notification' changes, where their implementation would not affect the established efficacy of the medicine. | N/A |
| L(A)C1 | Changes to the medicine label and ARTG entry that do not affect the efficacy of the medicine. | 30 working days |
| L(A)C2 | Changes that may affect the efficacy of the medicine. | 120 working days |

Table 18 Assessed listed medicine applications by outcome

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| New medicines | | |
| Approved | 2 (67%) | 0 (0%) |
| Refused | 1 (33%) | 1 (100%) |
| Withdrawn | 0 (0%) | 0 (0%) |
| Failed screening | 0 (0%) | 0 (0%) |
| Total | 3 (100%) | 1 (100%) |

Table 19 Applications received for new Assessed listed medicines and changes to existing medicines

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| New medicine applications | | |
| L(A)1 | 0 (0%) | 0 (0%) |
| L(A)2 | 0 (0%) | 0 (0%) |
| L(A)3 | 1 (100%) | 2 (100%) |
| Total | 1 (100%) | 2 (100%) |
| Change applications | | |
| CN | 0 (0%) | 0 (0%) |
| C1 | 1 (100%) | 1 (100%) |
| C2 | 0 (0%) | 0 (0%) |
| Total | 1 (100%) | 1 (100%) |

2. Listed Medicines

Listed medicines are considered to be of relatively lower risk than other medicines on the basis that they can only contain pre-approved ingredients and indications. Unlike registered medicines, we do not assess each listed medicine before it goes onto the market. However, we do require sponsors to certify that the medicine complies with all relevant legislation, and that they hold evidence at the time of listing (and at all times) that their medicine does what it says it will.

We may select a listed medicine for a post-market review where we require the sponsor to provide evidence of compliance with regulatory requirements. This includes the assessment of compliance with standards, efficacy, labelling and advertising. If we find that the medicine does not comply with all applicable regulatory requirements, the medicine's listing may be suspended or cancelled.

* 1. New ingredients permitted for use in listed medicines

Table 20 New listed medicine ingredient applications by outcome

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Application outcome | | |
| Approved | 5 (38%) | 14 (56%) |
| Rejected | 3 (23%) | 4 (16%) |
| Withdrawn | 5 (38%) | 7 (28%) |
| Returned/failed screening | 0 (0%) | 0 (0%) |
| Total completed | 13 (100%) | 25 (100%) |

* 1. Indications permitted for use in listed medicines

Table 21 Permitted indication applications by outcome

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Application outcome | | |
| Approved | 3 (43%) | 0 (0%) |
| Rejected | 3 (43%) | 3 (75%) |
| Withdrawn | 1 (14%) | 1 (25%) |
| Total completed | 7 (100%) | 4 (100%) |

* 1. New listed medicines

Table 22 New listed medicines

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| New listed medicines | 2,184 | 1,929 |

* 1. Variations

Table 23 Listed medicine variations under subsection 9D(1) of the Act

Subsection 9D(1) of the *Therapeutic Goods Act 1989* provides for variations to be made to an entry on the ARTG where information included on the ARTG is incomplete or incorrect. These variations are considered by a delegate. Other types of variations to listed medicines are applied for and processed automatically by the online application system.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Medicine variation | | |
| Approved | 142 (88%) | 178 (88%) |
| Rejected | 2 (1%) | 0 (0%) |
| Withdrawn | 18 (11%) | 24 (12%) |
| Total | 162 (100%) | 202 (100%) |

* 1. Post-market applications

Table 24 Listed medicine post-market applications

After listing, it may be necessary for the TGA to consider an application to support compliance with various requirements. The TGA receives applications for consents under sections 14 and 14A of the Act (which provides consent to import, supply or export therapeutic goods that do not comply with applicable standards). Additionally, some listed medicines require pre-clearance, in order to supply a batch of medicine that contains ingredients that are at risk of containing aristolochic acids (which is a toxic substance). The TGA also receives applications under subsection 7(2) of the Act, to declare whether a type of product is/is not a therapeutic good under section 7 of the Act.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Applications Assessed | | |
| Aristolochic Acid clearances | | |
| Approved | 40 | 45 |
| Rejected | 2 | 2 |
| Total number of clearances | 42 | 47 |
| Consents under section 14/14A of the Act | | |
| Approved | 31 | 5 |
| Extensions a | 0 | 582 |
| Rejected | 4 | 1 |
| Withdrawn | 1 | 0 |
| Total number of consents | 36 | 588 |
| Section 7 declaration | | |
| Approved | 0 | 0 |
| Rejected | 1 | 1 |
| Withdrawn | 0 | 0 |
| Total number of declarations | 1 | 1 |
| Total completed | 79 | 636 |

a Section 14 extensions were given to products that already held a consent to supply goods that did not comply with Section 9(2) of the Therapeutic Goods Order 92 – Labelling that was due to expire in September 2021.

Table 25 Conditions of listing

The TGA may impose additional conditions of listing on products after listing. Some of these apply to all listed medicines and are automatically applied at the time of listing, while some only apply to certain products and these sponsors are notified after their products are listed in the ARTG. Currently the product-specific conditions of listing are imposed on listed medicines that contain plant species that look very similar or have a name that sounds very similar to plant species that are likely to contain aristolochic acids, as well as on sunscreen products to ensure they have appropriate SPF testing data following issues with AMA laboratories.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Product specific conditions of listing | | |
| Aristolochic Acid | 27 | 3 |
| Sunscreens a b | 818 | 296 |
| Total | 845 | 299 |

a Letter sent to all sponsors in the ARTG when the new condition was imposed

b Letter only sent to new sunscreen listings in this period

* 1. Enquiries and education activities

Table 26 Enquiries and education

The TGA responds to stakeholder enquiries related to the regulation of listed medicines, including Food Medicine Interface (FMI) and Cosmetic Medicine Interface (CMI) enquires. To help address frequently asked questions or areas where consistent compliance issues are observed in listed medicines, the TGA provides educational presentations for external stakeholders (e.g., at conferences and seminars) and fact sheets for FMI/CMI issues. The TGA also responds to listed medicine-related enquiries related to educational information sent to stakeholders.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Enquiries and education actions | | |
| General enquiries about non-prescription medicines (OTC, listed medicines, Registered Complementary medicines)- emails | 4,826 | 3,648 |
| General enquiries about non-prescription medicines (OTC, listed medicines, Registered Complementary medicines)- emails – phone calls | 843 | 627 |
| FMI/CMI related enquires | 25 | 33 |
| Guidelines, media releases, factsheets, educational web content, social media posts a | N/A | 13 |
| FMI/CMI educational correspondences (e.g. follow up on fact-sheet) a | N/A | 4 |

a data unavailable or process was not in existence

* 1. Food/Cosmetic-Medicine Interface activities

Table 27 Food Medicine Interface (FMI) and Cosmetic Medicine Interface (CMI) assessments

FMI/CMI referrals may come from internal and external stakeholders. Some externals stakeholders include Food Standards Australia New Zealand and the state and territory food regulators, the Australian Border Force, and the Australian Federal Police. Referrals are also received through consumers and industry members. All referrals are triaged based on risk to consumers.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| FMI/CMI assessments | | |
| FMI/CMI referrals triaged and queued | 63 | 60 |
| FMI/CMI referrals triaged and closed via factsheet a b | N/A | 8 |
| Completed FMI/CMI assessments | 47 | 38 |
| Referral to another TGA area or government organisation | 44 | 32 |

a Using factsheet developed in Table 26

b data unavailable or process was not in existence

* 1. Compliance and enforcement

Signals of non-compliance related to listed medicines that are handled by the TGA mainly include complaints and referrals from external or internal stakeholders and weekly scanning of recently listed medicines on the ARTG. The ARTG scanning allows the detection of potential non-compliance of a medicine prior to the sponsor marketing the medicine. Early engagement with the sponsor soon after their listing also allows sponsors to update their product before they suffer commercial losses.

Signals of potential non-compliance are triaged and assessed for alleged breaches, and actions taken are dependent on the risks posed. Actions from signals can include low level compliance actions such as an educational correspondence, or an in-depth investigation may be conducted that may result in medium to high level compliance or enforcement actions such as a warning letter, a compliance review or infringement notices.

Targeted compliance reviews may be initiated as a result of signals investigations or from intel/data that is available regarding a compliance topic. When issues identified in a signal investigation is found to be of high risk, a compliance review will be triggered to conduct a more in-depth investigation and/or take further enforcement action.

A compliance review will result in one of the following outcomes:

* no compliance breaches are identified against selected listing requirements, the review is concluded, and the medicine remains on the ARTG
* compliance breaches are identified for the selected listing requirements
* the review is not completed as the sponsor has cancelled the medicine
* the review is closed due to the unavailability of information in determining its compliance status as the medicine is yet to be manufactured.

The TGA publishes results of listed medicine compliance reviews on the TGA website to assist consumers to make informed choices about whether a listed medicine is appropriate for them.

The 2021-22 compliance strategy for listed medicines mainly included targeted compliance activities based on intel/data. In the future, more random reviews (random selection of listed medicines for audit) will be used to assess the impact of our targeted strategy to measure compliance rates more broadly.

Table 28 Signals triaging and investigations

|  |  |
| --- | --- |
| 2020-21 | 2021-22 |
|  | **July to June** | |
| Signals monitored | | |
| Newly listed medicines monitored | 1,947 | 2,115 |
| Leads (complaints and referrals) received | 54 | 42 |
| Signals of non-compliance risk assessed and investigated a | 78 | 221 |
| Signals of non-compliance resolved through low to medium level compliance actions b (% success c) | 54 d | 41 (53%) |
| Signals of non-compliance transitioned to a compliance review | 21 | 19 |

a This process changed between the 2020-21 and 2021-22 financial years. In 2020/21, all flagged signals were investigated, whereas in 2021/22, flagged signals were risk assessed to determine whether an investigation is warranted, while lower risk signals were logged for monitoring.

b E.g. obligations notice or educational correspondence

c Success is measured as a percentage of medicines brought into compliance voluntarily by sponsors after receiving a low to medium level compliance action

d Process for checking effectiveness of these actions in bringing about compliance commenced in March 2022, as such data unavailable for 2020/21.

Table 29 Listed medicine compliance reviews by type

| 2020-21 | 2021-22 |
| --- | --- |
|  | **July to June** | |
| Initiated reviews | | |
| Compliance reviews | 70 | 52 |
| Compliance reviews transitioned from signal investigations | 30 | 19 |
| Total number of initiated reviews | 100 | 71 |
| Reviews on hand | 133 | 140 |
| Completed reviews | | |
| Compliance reviews | 40 | 49 |
| Compliance reviews transitioned from signal investigations | 36 | 29 |
| Total number of completed reviews | 76 | 78 |

Table 30 Compliance and enforcement actions

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Compliance and enforcement actions |  |  |
| Cease review notices | 33 | 6 |
| Conclusion notices | 7 | 19 |
| Educational correspondence (e.g. obligations notices, educational emails) | 43 | 91 |
| Deficiencies notices | 8 | 13 |
| Warning notices (cease and desist) | 11 | 6 |
| Proposal to cancel notices | 30 | 28 |
| Cancellation notices | 5 | 2 |
| Directions/Prevention notice | 0 | 1 |
| Infringement notices | 9 | 6 |
| Published outcomes of compliance reviews | 84 | 78 |
| Referral to another TGA area or government organisation | 6 | 17 |
| Total actions undertaken a | 237 | 270 |

a An investigation or review may give rise to more than one action

Table 31 All compliance review a outcomes

|  | 2020-21 | 2021-22 |
| --- | --- | --- |
|  | **July to June** | |
| Compliance status determined | | |
| Medicines with no compliance breaches | 6 | 21 |
| Medicines with verified compliance breaches: | 39 | 50 |
| Medicine no longer on the ARTG | | |
| Cancelled by the TGA | 4 | 3 |
| Cancelled by the sponsor after being notified of the compliance breaches | 19 | 23 |
| Medicine remains on the ARTG | | |
| Compliance breaches addressed after low level compliance action b | 6 | 14 |
| Compliance breaches addressed after proposal to cancel | 10 | 10 |
| Sub-total | 45 | 71 |
| Compliance status unable to be determined | | |
| Medicines cancelled by sponsors after request for information | 23 | 7 |
| Medicines not yet manufactured | 8 | 0 |
| Sub-total | 31 | 7 |
| Product is not a therapeutic good | 0 | 0 |
| Total completed | 76 | 78 |

a All compliance reviews, including those that transitioned from signal investigations

b E.g., deficiencies/obligations/warning notices

Table 32 Reach of compliance activities for listed medicines

In this table, compliance interactions include letters such as obligations notices, deficiency notices as well as other educational correspondences such as targeted educational email campaigns and direct email communications with sponsors. Compliance interactions includes all activities conducted for listed medicines, from applications and applying conditions of listing, through to signal investigations and compliance reviews.

Indirect reach of our compliance activities such as through reading media releases, publication of compliance review outcomes, publication of infringement/prevention notices have not been captured here.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Sponsors reached | | |
| Sponsors who received any compliance interactions | 247 (10%) | 226 (10%) |
| Listings covered by any compliance interactions | 1509 (14%) | 609 (5%) |

Figure 3 a Outcomes of completed compliance reviews

a A significant proportion of listed medicine reviews are concluded after the sponsor has adequately addressed the compliance breaches identified by us. Under the *Therapeutic Goods Act 1989* sponsors are given an opportunity to respond to issues raised during a compliance review.

|  |  |  |
| --- | --- | --- |
| **Figure 3 Outcomes of completed compliance reviews** | **Count** | **Percentage** |
| Cancelled by Sponsors after TGA contact | 30 | 38% |
| Cancelled by TGA after proposal to cancel | 3 | 4% |
| Compliant after proposal to cancel | 10 | 13% |
| Compliant after education | 14 | 18% |
| Compliant | 21 | 27% |
| **Total** | **78** | **100%** |

**Types of listed medicine compliance issues identified**

The following is a summary of the types of issues identified in the completed compliance activities (signals investigations and compliance reviews). Each review or investigation of a medicines may identify multiple issues. Compliance reviews can be further divided into 2 categories, whether they are triggered by signals investigations or not. When issues identified in a signal investigation is found to be of high risk, a compliance review will be triggered to conduct a more in-depth investigation and/or take further enforcement action.

Table 33 Issues identified in compliance reviews (excluding compliance reviews transitioned from signals investigations)

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Type of compliance issue |  | |
| Information provided in ARTG entry a | 2 (4%) | 4 (11%) |
| Manufacturing, quality and/or formulation | 3 (6%) | 6 (16%) |
| Labelling | 15 (31%) | 9 (24%) |
| Advertising | 14 (29%) | 9 (24%) |
| Unacceptable presentation b | 0 (0%) | 3 (7%) |
| Evidence c | 12 (25%) | 4 (11%) |
| Safety d | 0 (0%) | 0 (0%) |
| Non-response to a request for information e | 0 (0%) | 0 (0%) |
| Other f | 2 (4%) | 3 (7%) |
| Total | 48 (100%) | 38 (100%) |

a ‘ARTG information’ broadly refers to situations where the information on the ARTG is incorrect, including indications that are not eligible for listing and ingredients that do not comply with listing requirements.

b ‘Unacceptable presentation’ means that aspects such as name, labelling, packaging, advertising or other material state or suggest that the medicine has ingredients, components or characteristics that it does not have.

c ‘Evidence’ means the evidence held by the sponsor does not support the claims relating to the medicine.

d ‘Safety’ means that the medicine is not safe for the purposes for which it is to be used.

e In previous reports ‘other’ included non-response to a request for information. However, this is now being reported separately.

f ‘Other’ compliance issues may include the sponsor failing to comply with a condition that the medicine is subject to.

Table 34 Issues identified in compliance reviews transitioned from signals investigations

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)\*** | |
| Type of compliance issue |  | |
| Information provided in ARTG entry a | 10 (29%) | 13 (29%) |
| Manufacturing, quality and/or formulation | 0 (0%) | 6 (13%) |
| Labelling | 12 (35%) | 15 (33%) |
| Advertising | 10 (29%) | 7 (16%) |
| Unacceptable presentation b | 1 (3%) | 3 (7%) |
| Evidence c | 1 (3%) | 0 (0%) |
| Safety d | 0 (0%) | 0 (0%) |
| Non-response to a request for information e | 0 (0%) | 0 (0%) |
| Other f | 0 (0%) | 1 (2%) |
| **Total** | 34 (100%) | 45 (100%) |

a ‘ARTG information’ broadly refers to situations where the information on the ARTG is incorrect, including indications that are not eligible for listing and ingredients that do not comply with listing requirements.

b ‘Unacceptable presentation’ means that aspects such as name, labelling, packaging, advertising or other material state or suggest that the medicine has ingredients, components or characteristics that it does not have.

c ‘Evidence’ means the evidence held by the sponsor does not support the claims relating to the medicine.

d ‘Safety’ means that the medicine is not safe for the purposes for which it is to be used.

e In previous reports ‘other’ included non-response to a request for information. However, this is now being reported separately.

f ‘Other’ compliance issues may include the sponsor failing to comply with a condition that the medicine is subject to.

\*all percentages have been rounded up

Table 35 Issues identified in signals investigations (i.e., fully investigated signals that did not transition to compliance reviews)

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Type of compliance issue |  | |
| Information provided in ARTG entry a | 18 (12%) | 49 (31%) |
| Manufacturing, quality and/or formulation | 18 (12%) | 5 (3%) |
| Labelling | 20 (14%) | 23 (15%) |
| Advertising | 67 (45%) | 56 (35%) |
| Evidence b | 10 (7%) | 12 (8%) |
| Safety c | 10 (7%) | 7 (4%) |
| Other d | 4 (3%) | 6 (4%) |
| **Total** | 147 (100%) | 158 (100%) |

a ‘ARTG information’ broadly refers to situations where the information on the ARTG is incorrect, including indications that are not eligible for listing and ingredients that do not comply with listing requirements.

b ‘Evidence’ means the evidence held by the sponsor does not support the claims relating to the medicine.

c ‘Safety’ means that the medicine is not safe for the purposes for which it is to be used.

d ‘Other’ compliance issues may include the sponsor failing to comply with a condition that the medicine is subject to.

\*all percentages have been rounded up/down

Figure 4 Types of compliance issues identified by reason for initiation

|  |  |  |  |
| --- | --- | --- | --- |
| **Figure 4 Types of compliance issues identified by reason for initiation** | **Compliance reviews** | **Signals investigations reviewsa** | **Signal investigations** |
| Advertising | 9 (23%) | 7 (16%) | 56 (35%) |
| Evidence | 4 (11%) | 0 (0%) | 12 (8%) |
| Information provided in ARTG entry | 4 (11%) | 13 (29%) | 49 (31%) |
| Labelling | 9 (23%) | 15 (33%) | 23 (15%) |
| Manufacturing, quality and/or formulation | 6 (16%) | 6 (13% | 5 (3%) |
| Non-Response | 0 (0%) | 0 (0%) | 0 (0%) |
| Other | 3 (8%) | 1 (2%) | 6 (4%) |
| Safety | 0 (0%) | 0 (0%) | 7 (4%) |
| Unacceptable presentation | 3 (8%) | 3 (7%) | 0 (0%) |
| **Total** | **38 (100%)** | **45 (100%)** | **158 (100%)** |

a Compliance reviews transitioned from signal investigations

1. 6. Biologicals and Blood Components
   1. Inclusion of biologicals

Table 36 Applications for biologicals a and blood received and on hand

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Applications received | | |
| Technical Master File (TMF)b new | 0 (0%) | 0 (0%) |
| TMF annual updates | 3 (5%) | 3 (3%) |
| TMF variations | 7 (12%) | 6 (6%) |
| TMF notifications | 7 (12%) | 5 (5%) |
| Plasma Master File c annual updates | 14 (25%) | 12 (11%) |
| Biological Class 1 – new applications | 2 (4%) | 1 (1%) |
| Biological Class 2 – new applications | 5 (9%) | 5 (5%) |
| Biological Class 3 – new applications | 0 (0%) | 0 (0%) |
| Biological Class 4 – new applications | 4 (7%) | 3 (3%) |
| Biological Class 2 – variations | 8 (14%) | 24 (23%) |
| Biological Class 3 – variations | 1 (2%) | 10 (10%) |
| Biological Class 4 – variations | 6 (10%) | 35 (33%) |
| Total received | 57 (100%) | 104 (100%) |
| Applications on hand | | |
| TMF new | 0 (0%) | 0 (0%) |
| TMF annual updates | 1 (5%) | 1 (4%) |
| TMF variations | 2 (10%) | 2 (9%) |
| TMF notifications | 1 (5%) | 1 (4%) |
| Plasma Master File annual updates | 6 (30%) | 2 (9%) |
| Biological Class 1 – new applications | 0 (0%) | 0 (0%) |
| Biological Class 2 – new applications | 5 (25%) | 3 (14%) |
| Biological Class 3 – new applications | 0 (0%) | 0 (0%) |
| Biological Class 4 – new applications | 2 (10%) | 3 (14%) |
| Biological Class 2 – variations | 3 (15%) | 5 (18%) |
| Biological Class 3 – variations | 0 (0%) | 3 (14%) |
| Biological Class 4 – variations | 0 (0%) | 3 (14%) |
| Total on hand | 20 (100%) | 23 (100%) |

a The *Australian Regulatory Guidelines for Biologicals* (published on our [website](https://www.tga.gov.au/publication/australian-regulatory-guidelines-biologicals-argb)) define the different biological classes.

b Technical Master Files (TMF) contain information from manufacturers that demonstrate how product safety and quality standards have been met for Blood, Blood Components and Haematopoietic Progenitor Cells.

c Plasma Master Files contain control strategies that ensure the quality and safety of plasma, from collection through to plasma pooling prior to fractionation and including donor selection criteria and testing, which are part of medicinal products or medical devices.

Table 37 Completed applications for biologicals and blood

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Biologicals applications | | |
| Technical Master File (TMF) new | 0 (0%) | 0 (0%) |
| TMF annual updates | 3 (5%) | 3 (3%) |
| TMF variations | 6 (10%) | 4 (4%) |
| TMF notifications | 8 (14%) | 4 (4%) |
| Plasma Master File annual updates | 8 (14%) | 10 (11%) |
| Biological Class 1 – new applications | 2 (4%) | 1 (1%) |
| Biological Class 2 – new applications | 1 (2%) | 2 (2%) |
| Biological Class 3 – new applications | 1 (2%) | 0 (0%) |
| Biological Class 4 – new applications | 2 (4%) | 1 (1%) |
| Biological Class 2 – variations | 14 (24%) | 19 (22%) |
| Biological Class 3 – variations | 2 (4%) | 12 (13%) |
| Biological Class 4 – variations | 10 (17%) | 35 (39%) |
| Total completed | 57 (100%) | 91 (100%) |

1. 7. Medicine and Vaccine Adverse Event Reports
   1. Adverse medicine and vaccine reaction notifications

Table 38 Source of notifications of medicine and vaccine adverse reactions a

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Received | | |
| Mean number of reports received weekly | 1,174 | 2,421 |
| Vaccine reports | 41,586 | 107,958 |
| Total | 61,038 | 125,873 |
| Accepted cases | | |
| Reports by health professionals | 8,446 | 11,610 |
| Patients/consumers | 9,140 | 27,428 |
| Pharmaceutical companies | 14,055 | 15,950 |
| Other sourceb | 27,076 | 66,096 |
| Total | 58,717 | 121,084 |
| Rejected/withdrawn cases | 2,321 | 4,789 |

a Data is subject to change due to receipt of further information related to individual reports or further case processing. Notifications for 2020-21 have been updated since the last Regulator Performance Report to reflect the most recent data.

b ‘Other source’ includes reports received from state and territory health departments (accounting for >99% of these reports) as well as reports received from other organisations that are not pharmaceutical companies.

1. 8. Medical Devices

The Medical Devices Regulatory Framework spans the life cycle for these products, including:

* **Priority review of medical devices**:Thispathway allows faster processing of applications for devices that meet certain criteria such as being a novel device or delivering significant health benefits above those devices already on the market.
* **Medical device manufacturing:** The TGA assesses the quality management systems of medical device manufacturers seeking TGA conformity assessment certification. This may be through onsite inspections or desktop assessment of third-party inspection reports, or a combination of these methods. Surveillance inspections are also undertaken to assess continuing compliance. In addition, the TGA is a Regulatory Authority of the Medical Devices Single Audit Program (MDSAP) that assesses and recognises third party Auditing Organisations for the purposes of certifying medical device manufacturers.
* **Conformity assessment:** Thisis the systematic examination by the manufacturer to determine that a medical device is safe and performs as intended and therefore, conforms to the Essential Principles. Certification of the manufacturer’s conformity assessment procedure may (or for particular products, must) be undertaken by the TGA, or we may recognise conformity assessment certification from comparable regulators in other jurisdictions such as European notified bodies.
* **Inclusion on the ARTG:** Medical devices cannot be imported, supplied in, or exported from Australia unless they are included on the ARTG or a valid exemption applies, for example custom made medical devices, importation of samples, etc. A sponsor can apply to include a medical device on the ARTG if the device complies with the Essential Principles and appropriate conformity assessment procedures have been applied to the device.
* **Post-market monitoring:** Once a medical device has been included on the ARTG the device must continue to meet all the regulatory, safety and performance requirements and standards that were required for the approval.
  1. Conformity assessment

#### Applications

Table 39 Number of conformity assessment applications (medical devices including IVDs)

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Conformity assessment applications | | |
| Applications received | 328 | 191 |
| Applications on hand | 256 | 169 |
| Applications completed (including withdrawn or lapsed applications). | 294 | 278 |

#### Outcomes

Table 40 Outcomes of conformity assessment applications

|  | **2020-21** | | **2021-22** |
| --- | --- | --- | --- |
|  | | **July to June** | |
| New | | | |
| Approved | 38 | | 51 |
| Rejected | 0 | | 0 |
| Withdrawn/ Lapsed | 39 | | 36 |
| Variation (changes and re-certifications) | | | |
| Approved | 192 | | 162 |
| Rejected | 0 | | 0 |
| Withdrawn/ Lapsed | 25 | | 29 |

#### Processing timeframes

We are required to complete our review of conformity assessment applications within 255 working days.

Table 41 TGA processing times for new devices and variations

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| New devices | | |
| Mean TGA processing time (days) a | 157 | 139 |
| Median TGA processing time (days) a | 200 | 168 |
| % of applications completed within legislated timeframe  (255 working days) | 100% | 100% |
| Variations (changes and recertifications) | | |
| Mean TGA processing time (days) | 124 | 146 |
| Median TGA processing time (days) | 117 | 168 |
| % of applications completed within legislated timeframe  (255 working days) | 100% | 100% |

a Note that 26 applications were withdrawn prior to six TGA days processing time

* 1. Inclusion of medical devices (including IVDs)

#### Applications

Table 42 Applications for inclusion – medical devices (including IVDs)

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Class I medical devices |  |  |
| Applications received | 3,632 | 2,365 |
| Applications completed | 3,436 | 2,259 |
| Applications on hand | 251 | 321 |
| Class I measuring medical devices |  |  |
| Applications received | 73 | 48 |
| Applications completed | 73 | 49 |
| Applications on hand | 3 | 1 |
| Class I sterile medical devices |  |  |
| Applications received | 318 | 279 |
| Applications completed | 308 | 298 |
| Applications on hand | 19 | 16 |
| Class IIa medical devices |  |  |
| Applications received | 1,579 | 1,377 |
| Applications completed | 1,544 | 1,451 |
| Applications on hand | 105 | 79 |
| Class IIb medical devices |  |  |
| Applications received | 646 | 610 |
| Applications completed | 655 | 644 |
| Applications on hand | 88 | 100 |
| Class III medical devices |  |  |
| Applications received | 501 | 469 |
| Applications completed | 365 | 463 |
| Applications on hand | 311 | 297 |
| Active Implantable Medical Devices (AIMD) | | |
| Applications received | 20 | 21 |
| Applications completed | 53 | 19 |
| Applications on hand | 9 | 23 |
| Class 1 IVDs a |  |  |
| Applications received | 125 | 151 |
| Applications completed | 125 | 141 |
| Applications on hand | 7 | 17 |
| Class 2 IVDs |  |  |
| Applications received | 60 | 59 |
| Applications completed | 61 | 60 |
| Applications on hand | 10 | 9 |
| Class 3 IVDs |  |  |
| Applications received | 140 | 526 |
| Applications completed | 142 | 275 |
| Applications on hand | 43 | 294 |
| Class 4 IVDs |  |  |
| Applications received | 12 | 12 |
| Applications completed | 12 | 5 |
| Applications on hand | 0 | 7 |

a The number of applications for Class 1 IVD includes auto-included devices and applications completed with or without audit.

Table 43 Applications for device change requests and variations to the ARTG – medical devices (including IVDs)

|  | 2020-21 | 2021-22 |
| --- | --- | --- |
|  | **July to June** | |
| Device Change Request (DCR) |  |  |
| Applications received | 959 | 1,035 |
| Applications completed | 952 | 951 |
| Applications on hand | 132 | 310 |
| Variations to Class III medical devices |  |  |
| Applications received | 97 | 117 |
| Applications completed | 88 | 123 |
| Applications on hand | 18 | 8 |
| Variations to Active Implantable Medical Devices (AIMD) | | |
| Applications received | 3 | 0 |
| Applications completed | 2 | 1 |
| Applications on hand | 1 | 0 |
| IVD Device Change Request (DCR) | | |
| Applications received | 71 | 83 |
| Applications completed | 58 | 72 |
| Applications on hand | 24 | 35 |
| IVD Variations | | |
| Applications received | 109 | 97 |
| Applications completed | 85 | 100 |
| Applications on hand | 36 | 33 |

#### Processing times

A Level 1 audit may include clarification of the device classification, a conformity assessment procedure, and/or a review of packaging and labelling to ensure it meets requirements.

A Level 2 audit requires the information for a Level 1 audit plus one or more of the following: clinical evidence, risk management report(s), efficacy, and performance data, and/or audit reports from Notified Bodies. The target timeframe for Level 1 application audits is 30 TGA workdays and for Level 2 application audits is 60 TGA workdays (reflected in ‘TGA days’).

Table 44 Processing times for medical device application audits (including IVDs)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **2020-21** | | | **2021-22** | | |
|  | **Total completed** | **Processing times (TGA days)** | | **Total completed** | **Processing times (TGA days)** | |
| **Mean** | **Median** | **Mean** | **Median** |
| Medical devices | | | | | | |
| Class I applications completed without audit | 3,109 | 1 | 1 | 1,533 | 2 | 1 |
| Class I applications completed with audit | 440 | 3 | 1 | 763 | 39 | 15 |
| Non class I applications completed without audit | 2,324 | 9 | 8 | 2,101 | 10 | 9 |
| Non-compulsory audits (Non class I) | 100 | 95 | 49 | 106 | 90 | 44 |
| Level 1 compulsory audits | 30 | 49 | 62 | 41 | 27 | 14 |
| Level 2 compulsory audits | 266 | 153 | 136 | 269 | 190 | 165 |
| IVDs | | | | | | |
| Class I IVD applications completed without audit | 91 | 1 | 1 | 82 | 2 | 1 |
| Class I IVD applications completed with audit | 17 | 37 | 28 | 37 | 26 | 10 |
| Non class I IVD applications completed without audit | 57 | 3 | 2 | 72 | 2 | 1 |
| IVD non-compulsory audit | 6 | 36 | 20 | 3 | 23 | 22 |
| IVD compulsory audit | 128 | 61 | 46 | 219 | 48 | 35 |
| IVD Device Change Request | 58 | 48 | 51 | 72 | 67 | 67 |
| IVD Variation | 85 | 37 | 32 | 100 | 67 | 67 |

Table 45 Number of priority review determinations a granted

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July-June** | |
| Application type | | |
| A: Conformity Assessment (priority applicant) determinations b | 2 | 0 |
| B: Medical Devices (priority applicant) determinations b | 0 | 0 |

a Priority designation is a formal decision by the TGA to assign priority to the assessment of an application to include a medical device in the ARTG. Granting of priority designation does not guarantee approval for the application itself.

b No determinations were granted in 2021-22.

Table 46 Number of medical devices approved through the priority review pathway

|  |  |  |
| --- | --- | --- |
|  | 2021-22 | |
|  | **July-June** | |
| Application Type | Number of applications with Priority determinations Approved (% of Total) | Median approval time (TGA working days) |
| A: Conformity Assessment | 0 | N/A |
| B: Medical Devices (ARTG inclusion) | 0 | N/A |
| Total a | 0 | N/A |

a No applications were approved in this reporting period

* 1. Post-market monitoring

#### Compliance reviews

In previous years, Class I medical devices were included in the ARTG following an online self-certification by the sponsor through a computer-generated decision process. The TGA would undertake, when necessary, a post-market compliance review for these devices. The targeted review process included surveillance of all new Class I inclusions for potentially inappropriately included Class I devices, identified by the intended purpose having certain words indicative of risk, or known issues relating to the device. The inclusion process changed from October 2020, with all new Class I medical device, Class 1 IVD medical devices, and export only ARTG applications now reviewed prior to inclusion. Requests for information are sent out where there may be uncertainty regarding the appropriateness of the classification of the device for inclusion in the ARTG.

We also conduct targeted compliance reviews initiated on a case-by-case basis. These may be conducted for devices of any Class.

#### Post-market reviews

Post-market reviews ensure that medical devices continue to comply with the applicable regulatory requirements and that the safety and performance of the medical devices (including IVDs) are maintained. The TGA uses information from both internal (for example, increase trend in adverse events) and external sources (for example, reports of new hazards) to select medical devices for post-market review.

Table 47 Medical device targeted reviews

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Post market reviews | | |
| Reviews commenced – number of ARTG entries | 1,658 | 5,049 |
| Reviews completed – number of ARTG entries | 851 | 2,554 |
| Reviews on hand – number of ARTG entries | 3,246 | 5,741 |

#### Medical device incident reports

A medical device incident is an event associated with the use or misuse of a medical device that resulted in or could have resulted in (near-incident): serious injury, illness or death to a patient, healthcare worker or other person. Australian sponsors of medical devices must actively monitor their devices’ post market performance and report incidents to the TGA. Reporting of incidents, or near-incidents, by users is voluntary.

The target timeframe for processing medical device incident reports is 90 working days.

Table 48 Number of medical device incident reports and processing times

|  |  |
| --- | --- |
| 2020-21 | 2021-22 |
|  | **July to June** | |
| **Incident report outcomes** | | |
| Device incident reports a | | |
| Reports received | 6,142 | 8,737 |
| Reports completed | 6,010 | 7,978 |
| Reports still in progress | 183 | 207 |
| Processing time | | |
| Mean TGA processing time (days) | 13 | 23.2 |
| Median TGA processing time (days) | 4 | 6 |
| Percentage processed within target timeframe | 97% | 94% |

a Each year begins with a number of reports on hand, additional reports are received throughout the financial year and close out some of the reports on hand.

Table 49 Medical device incident report outcomes a

|  |  |
| --- | --- |
| 2020-21 | 2021-22 |
|  | **July to June** | |
| Incident report outcome | | |
| Reviewed and used for trend analysis purposes | 5,201 | 7,337 |
| Reviewed, no further action required | 518 | 426 |
| Product recall | 17 | 66 |
| Product device correction | 46 | 90 |
| Hazard alert | 5 | 32 |
| Product notification | 1 | 12 |
| Safety alert | 4 | 10 |
| Product enhancement/improvement notice | 1 | 2 |
| Instructions for use amended | 7 | 10 |
| Referral for post-market review | 59 | 39 |
| Refer to another TGA Branch or Section | 20 | 26 |
| Company warned | 5 | 0 |
| Product suspended from ARTG | 11 | 1 |
| Product cancelled from ARTG | 19 | 14 |
| Manufacturing process improvements | 7 | 8 |
| Quality system process improvements | 5 | 2 |
| Maintenance carried out by the hospital | 0 | 4 |
| Change to design | 8 | 6 |
| Not device related | 9 | 2 |
| TGA Publication | 0 | 20 |
| User education | 0 | 6 |
| Other | 151 | 29 |

a Outcomes are not mutually exclusive.

#### Devices manufacturing

Table 50 Outcomes of Quality Management System (QMS) audits of Australian manufacturers

Note: Due to travel restrictions related to COVID-19, the onsite/remote/hybrid inspection process continued for domestic inspections and remote auditing was implemented for overseas inspections.

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| QMS audits (Australia) | | |
| Number of audits completed | 16 | 24 |
| Satisfactory compliance (of completed audits) | 13 (81%) | 19 (80%) |
| Marginal compliance (of completed audits) | 3 (19%) | 4 (16%) |
| Unacceptable compliance (of completed audits) | 0 (0%) | 1 (4%) |
| Number of incomplete audits a | 12 | 6 |
| Processing time | | |
| Initial audits conducted within 3 months of application | 44% | 33% |
| Re-audits conducted within 6 months of due date | 21% | 0% |

a Where the audit has been performed however the audit report or close out is not complete

Table 51 Outcomes of QMS audits of overseas manufacturers

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| QMS audits (overseas) | | |
| Number of desktop audits conducted | 31 | 54 |
| Number of onsite/remote audits conducted a | 2 | 7 |
| Satisfactory compliance (of completed onsite/remote audits) | 0 (0%) | 2 (29%) |
| Marginal compliance (of completed onsite/remote audits) | 0 (0%) | 0 (0%) |
| Unacceptable compliance (of completed onsite/remote audits) | 0 (0%) | 1 (14%) |
| Incomplete audits b | 2 (100%) | 4 (57%) |
| Processing time | | |
| Initial certification audits conducted within 6 months of application | 50% | 67% |
| Certification re-audits conducted within 6 months of due date | 0% | 0% |

a Remote audits conducted late in the financial year

b Where the audit has been performed however the audit report or close out is not complete. Overseas audits resumed in May 2022 following travel restrictions.

Table 52 Outcomes of MDSAP

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| MDSAP Assessments (overseas) | | |
| Number of auditing organisation assessments | 9 | 9 |
| Number of witnessed manufacturing audits | 5 | 3 |

1. 9. Disinfectants

Following regulatory amendments in 2018, disinfectants that includes claims (including virucidal claims) have been downregulated from registered products to listed products. Products that make ‘specific’ claims to kill micro-organisms such as viruses, spores, tuberculosis bacteria and fungi are required to be included on the ARTG as a listed other therapeutic good (OTG) before they are supplied to the market.

* 1. Disinfectants

#### Applications

Table 53 Applications for listing – listed OTG

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | **2021-22** |
|  |  |  | **July to June** |
| Listed OTG (Disinfectants) | | | |
| Applications received a | | | 120 |
| Applications completed b | | | 125 |
| Applications on hand c | | | 21 |

a Figures refer to applications received within the 2021-22 financial year

b Figures refer to completed applications with an outcome made in the 2021-22 financial year

c Figures refer to in-progress applications which were received in the 2021-22 financial year

Table 54 Outcomes of listed OTG applications

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | |  | | **2021-22** |
|  | |  | |  | | **July to June** |
|  | |  | |  | | **Number (% of Total)** |
|  | Approved/ Accepted | | Rejected/ Lapsed | | Withdrawn | Total of applications |
| Listed OTG (Disinfectants) a | 71 (57%) | | 4 (3.2%) | | 50 (40%) | 125 (100%) |

a Figures refer to completed applications with an outcome made in the 2021-22 financial year

1. 10. Exports
   1. Export only products

Table 55 Number of approved applications for export-only medicines and export certifications and relevant processing time for July 2021 to June 2022

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 2020-21 | 2021-22 | Target processing time (days) | 2020-21 | 2021-22 |
| **Total approved** | | **Average processing time (days)** | |
| Export-only medicines | | | | | |
| New applications | 255 | 286 | 30 | 27 | 27 |
| Variation and grouping applications | 132 | 147 | 30 | 25 | 21 |
| Export certification | | | | | |
| Medicines | 1,540 | 1,622 | 15 | 13 | 10 |
| Medical devices | 796 | 1,072 | 10 | 8 | 6 |

1. 11. Access to Unapproved Therapeutic Goods
   1. Special Access Scheme

The Special Access Scheme (SAS) refers to arrangements which provide for the import and/or supply of an unapproved therapeutic good for a single patient, on a case-by-case basis. For this reporting period, 3 pathways existed under the scheme, and they are categorised as follows:

* Category A is a **notification pathway** which can only be accessed by medical practitioners for patients who are seriously ill with a condition from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of early treatment.
* Category B is an **application pathway** which can be accessed by health practitioners for patients who do not fit the Category A definition. An approval letter from the TGA is required before the goods may be accessed.
* Category C is a **notification pathway** which allows health practitioners to supply goods that are deemed to have an established history of use without first seeking prior approval. The goods deemed to have an established history of use are specified in a list along with their indications and the type of health practitioner authorised to supply these products.

Any unapproved therapeutic good can potentially be supplied via the SAS although for drugs in Schedule 9 of the Poisons Standard and forbidden from supply in most states and territories.

Table 56 SAS medicine notifications and applications

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Category A notifications | | |
| Total Category A notifications | 39,675 (24%) | 25,305 (15%) |
| Category B applications | | |
| Approved | 102,877 (97%) | 121,938 (98%) |
| Cancelled | 28 (<1%) | 78 (<1%) |
| Withdrawn | 742 (1%) | 665 (<1 %) |
| Rejected | 7 (<1%) | 0 (0%) |
| Pending at end of reporting period | 2,486 (2%) | 1,411 (1%) |
| Total Category B applications | 106,140 (65%) | 124,092 (74%) |
| Category C notifications | | |
| Total Category C notifications | 16,814 (11%) | 19,399 (12%) |
| Total SAS notifications/applications received (all categories) | 162,629 (100%) | 168,796 (100%) |

Table 57 SAS medical device notifications and applications

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Category A notifications | | |
| Total Category A notifications | 5,641 (46%) | 3,662 (43%) |
| Category B applications | | |
| Approved | 5,398 (95%) | 3,559 (93%) |
| Cancelled | 9 (<1%) | 23 (<1%) |
| Withdrawn | 86 (2%) | 64 (2%) |
| Rejected | 16 (<1%) | 3 (<1%) |
| Pending at end of reporting period | 151 (3%) | 196 (5%) |
| Total Category B applications | 5,660 (46%) | 3,845 (45%) |
| Category C notifications | | |
| Total Category C notifications | 1,002 (8%) | 1,107 (13%) |
| Total SAS notifications/applications received (all categories) | 12,303 (100%) | 8,614 (100%) |

Table 58 SAS biological notifications and applications

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Category A notifications | | |
| Total Category A notifications | 78 (7%) | 74 (7%) |
| Category B applications | | |
| Approved | 399 (80%) | 239 (73%) |
| Cancelled | 5 (1%) | 14 (4%) |
| Withdrawn | 42 (8%) | 64 (20%) |
| Rejected | 1 (<1%) | 0 (0%) |
| Pending at end of reporting period | 54 (11%) | 9 (3%) |
| Total Category B applications | 501 (47%) | 326 (31%) |
| Category C notifications | | |
| Total Category C notifications | 485 (46%) | 663 (62%) |
| Total SAS notifications/applications received (all categories) | 1,064 (100%) | 1,063 (100%) |

* 1. Clinical trials

The Clinical Trial Notifications scheme provides an avenue through which unapproved therapeutic goods may be supplied for use solely for clinical trials. Unapproved therapeutic goods can include biologicals, devices or medicines or a combination of any of the 3 types of goods.

Table 59 Number of notifications for new clinical trials involving unapproved therapeutic goods received by therapeutic good type

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Therapeutic good type | | |
| Medicine | 495 (43%) | 483 (41%) |
| Device a | 171 (15%) | 166 (14%) |
| Biological | 7 (1%) | 10 (1%) |
| Medicine and device | 451 (40%) | 514 (43%) |
| Device and biological | 1 (<1%) | 4 (<1%) |
| Medicine and biological | 2 (<1%) | 4 (<1%) |
| Medicine, device and biological | 4 (<1%) | 4 (<1%) |
| Total | 1,131 (100%) | 1,185(100%) |

a  ‘Device’ includes both medical device and therapeutic device categories.

Table 60 Number of new clinical trial notifications involving unapproved therapeutic goods received by phase

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Clinical trial type | | |
| Phase 1 | 341 (30%) | 377 (32%) |
| Phase 2 | 291 (26%) | 303 (26%) |
| Phase 3 | 270 (24%) | 273 (23%) |
| Phase 4 | 49 (4%) | 53 (4%) |
| Device | 175 (16%) | 172 (14%) |
| Bioavailability/equivalence | 5 (<1%) | 7 (1%) |
| Total | 1,131 (100%) | 1,185 (100%) |

Table 61 Number of notifications for new clinical trials and variations to previously notified clinical trials, including non-fee attracting variations, involving unapproved therapeutic goods received by therapeutic good type

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Therapeutic good type | | |
| Medicine | 1,242 (37%) | 1,278 (32%) |
| Device a | 301 (9%) | 320 (8%) |
| Biological | 12 (<1%) | 16 (<1%) |
| Medicine and device | 1,741 (53%) | 2,344 (59%) |
| Device and biological | 8 (<1%) | 10 (<1%) |
| Medicine and biological | 4 (<1%) | 7 (<1%) |
| Medicine, device and biological | 10 (<1%) | 24 (<1%) |
| Total | 3,318 (100%) | 3,999 (100%) |

a Device includes both medical device and therapeutic device categories. Therapeutic device means therapeutic goods (other than biologicals) consisting of an instrument, apparatus, appliance, material or other article (whether for use alone or in combination), together with any accessories or software required for its proper functioning, which does not achieve its principal intended action by pharmacological, chemical, immunological or metabolic means.

A variation to a previously notified clinical trial may include an addition of a site(s), change to a therapeutic good, or change in principal investigator etc.

Table 62 Number of new clinical trials and variations a to previously notified clinical trials involving unapproved therapeutic goods received by phase

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Phases | | |
| Phase 1 | 933 (28%) | 1,200 (30%) |
| Phase 2 | 882 (27%) | 1,024 (26%) |
| Phase 3 | 1,080 (33%) | 1,311 (33%) |
| Phase 4 | 104 (3%) | 117 (3%) |
| Device | 306 (9%) | 338 (8%) |
| Bioavailability/equivalence | 13 (<1%) | 9 (<1%) |
| Total | 3,318 (100%) | 3,999 (100%) |

a A variation may include any change to a previously notified clinical trial such as an additional site, change to a therapeutic good, or change in principal investigator.

* 1. Authorised Prescribers

The Authorised Prescriber Scheme allows approved medical practitioners authority to prescribe a specified unapproved therapeutic good(s) to patients who are identified by their medical condition.

Table 63 Authorised Prescriber approvals for medicines, medical devices and biologicals

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Approvals by therapeutic good type | | |
| Number of approvals for medicines | 5,087 (94%) | 11,895 (98%) |
| Number of approvals for medical devices | 311 (6%) | 277 (2%) |
| Number of approvals for biologicals | 0 (0%) | 0 (0%) |
| Total | 5,398 (100%) | 12,172 (100%) |

* 1. Section 19A approvals

Section 19A of the *Therapeutic Goods Act 1989* provides the legislative basis for the Secretary of the Department of Health to approve the import or supply of an overseas registered medicine that is not included in the ARTG, to mitigate a shortage of a medicine.

Table 64 Section 19A applications

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Applications processed | | |
| New | 66 | 89 |
| Renewals | 61 | 52 |
| Total | 127 | 141 |

1. 12. Medicines and Biologicals Manufacturing
   1. Manufacturing licences issued to Australian manufacturers

Table 65 Status of manufacturing licence applications

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Licence status (Australia) a | | |
| New licences granted | 13 (14%) | 14 (16%) |
| Withdrawn application | 60 (65%) | 57 (67%) |
| Revoked licences – at request of licence holder | 15 (17%) | 10 (12%) |
| Revoked licences – TGA | 0 (0%) | 0 (0%) |
| Suspended – at request of licence holder | 4 (4%) | 4 (5%) |
| Suspended – TGA | 0 (0%) | 0 (0%) |
| Total | 92 (100%) | 85 (100%) |

a As at 30 June 2022, there were 265 Australian companies holding manufacturing licences covering 410 sites.

Table 66 Outcomes of inspections of Australian manufacturers

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Compliance status (Australia) | | |
| Number of inspections conducted | 210 | 139 |
| Satisfactory compliance (of completed inspections) | 139 (66%) | 99 (71%) |
| Marginal compliance (of completed inspections) | 35 (17%) | 25 (18%) |
| Unacceptable (of completed inspections) | 9 (4%) | 7 (5%) |
| Compliance under assessment | 27 (13%) | 8 (5%) |
| Processing time | | |
| Initial inspections conducted within 3 months of application | 8 of 12 (67%) a | 9 of 15 (60%) c |
| Re-inspections conducted within 6 months of due date | 117 of 162 (72%) b | 34 of 95 (36%) d |

a 4 domestic initial inspections did not achieve the three-month processing timeframe in 2020-21.

b 45 domestic re-inspections did not achieve the six-month processing timeframe. 18 pf the 45 delayed re-inspections were blood and biological manufacturers

c 6 domestic initial inspections did not achieve the three-month processing timeframe in 2021-22 due to the manufacturer not being ready for inspection.

d 61 domestic re-inspections did not achieve the six-month processing timeframe due to competing priorities with overseas inspections. 26 of the delayed re-inspections were blood and biological manufacturers.

* 1. Approval (certification) of overseas manufacturers

Table 67 Manufacturing certification application by status (overseas)

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Applications (overseas) a | | |
| New applications received b | 38 (36%) | 71 (61%) |
| Re-inspection applications b | 67 (64%) | 46 (39%) |
| Totalapplications | 105 (100%) | 117 (100%) |
| Applications completed | | |  | 0 (0%) |
| Certified | 38 (26%) | 71 (60%) |
| Rejected c | 111 (74%) | 48 (40%) |
| Total completed | 149 (100%) | 119 (100%) |

a As at 30 June 2022, there were 132 overseas manufacturers covering 150 manufacturing sites that are subject to TGA inspection.

b Refers to applications that generated an inspection, undertaken by the TGA.

c Rejections include withdrawn applications.

Table 68 Outcomes of inspections of overseas manufacturers

|  |  |  |
| --- | --- | --- |
|  | **2020-21** | **2021-22** |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Inspection status (overseas) | | |
| Number of inspections conducted | 54 | 104 |
| Satisfactory compliance (of completed inspections) | 41 (76%) | 80 (77%) |
| Marginal compliance (of completed inspections) | 4 (7%) | 17 (16%) |
| Unacceptable (of completed inspections) | 1 (2%) | 2 (2%) |
| Compliance under assessment at period end | 8 (15%) | 5 (0%) |
| Processing time | | |
| Initial certification inspections conducted within 6 months of application a c | 0 of 15 (0%) | 8 of 37 (22%) |
| Certification re-inspections conducted within 6 months of due date b d | 6 of 29 (21%) | 2 of 66 (3%) |

a 15 overseas initial inspections did not achieve the six-month processing timeframe.

b 23 overseas re-inspections did not achieve the six-month processing timeframe.

c 29 overseas initial inspections did not achieve the six-month processing timeframe due to the manufacturer not being ready for the inspection.

d 64 overseas re-inspections did not achieve the six-month processing timeframe due to competing priorities with other inspections due at the same time.

* 1. Good Manufacturing Practice (GMP) clearances

GMP clearance is required by an Australian sponsor when a step in the manufacture of a medicine or an Active Pharmaceutical Ingredient is manufactured overseas, and the manufacturing step is recorded on the ARTG.

Table 69 GMP clearance application status

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total completed)** | |
| Applications received | 7,604 | 9,007 |
| Applications completed | | |  | Applications completed |
| Approved | 6,778 (93%) | 8,103 (91%) |
| Rejected | 524 (7%) | 799 (9%) |
| Total completed | 7,302 (100%) | 8,902 (100%) |

Table 70 Number of GMP clearance applications received and completed by type from 1 July 2021 to 30 June 2022

|  |  |  |
| --- | --- | --- |
| Application Category | Applications received | Applications completed |
| Cancel | 6 | 6 |
| Extend | 3,422 | 3,444 |
| New | 1,653 | 1,710 |
| Reactivate | 52 | 51 |
| Variation | 3,874 | 3,691 |

Table 71 Number of GMP clearance applications actioned by pathway from 1 July 2021 to 30 June 2022

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Pathway | Applications received | Applications completed | Applications  Approved | Applications  not approved | |
| Compliance Verification | 158 | 1,379 | 1,315 | | 64 |
| Mutual Recognition Agreement | 3,151 | 3,165 | 3,027 | | 138 |

1. 13. Recalls
   1. Medicine recalls

Table 72 Medicine recalls by reason for recall

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Reason for recall | | |
| Adverse reactions | 12 (13%) | 2 (2%) |
| Foreign matter | 1 (1%) | 4 (5%) |
| Illegal supply | 3 (3%) | 1 (1%) |
| Impurity | 2 (2%) | 10 (13%) |
| Labelling or Instructions | 34 (35%) | 24 (31%) |
| Mechanical or Physical defect | 5 (5%) | 4 (5%) |
| Microbial/Fungal contamination | 1 (1%) | 6 (8%) |
| Observed difference | 3 (3%) | 2 (2%) |
| Packaging or closure defect | 11 (12%) | 10 (13%) |
| Potency | 5 (5%) | 3 (4%) |
| Sterility | 5 (5%) | 3 (4%) |
| Variable content | 5 (5%) | 3 (4%) |
| Other a | 9 (10%) | 6 (8%) |
| Total | 96 (100%) | 78 (100%) |

a ‘Other’ includes bioavailability, diagnostic inaccuracy, disintegration or dissolution, GMP non-compliance, therapeutic inefficiency, viral/prion contamination, wrong product, and unknown.

* 1. Medical device recalls

Table 73 Medical device (including IVDs) recalls by reason for recall

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Reason for recall | | |
| Adverse incidents | 1 (<1%) | 2 (<1%) |
| Diagnostic inaccuracy | 40 (6%) | 25 (4%) |
| Electrical defect | 34 (5%) | 13 (2%) |
| Illegal supply | 2 (<1%) | 0 (0%) |
| Labelling and packaging | 132 (20%) | 115 (17%) |
| Mechanical and physical defects | 226 (34%) | 285 (43%) |
| Software defects | 166 (25%) | 170 (26%) |
| Sterility | 25 (4%) | 11 (2%) |
| Other a | 39 (6%) | 43 (6%) |
| Total | 665 (100%) | 664 (100%) |

a. ‘Other’ includes bioavailability, disintegration/dissolution, microbial contamination, variable content, foreign matter, impurity, wrong product, therapeutic inefficiency and observed differences.

* 1. Blood and Biological recalls

Table 74 Blood recalls

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Recalls to hospital level | 101 | 71 |

Table 75 Biological recalls

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Recalls to hospital level | 18 | 6 |

2. 14. Laboratory Testing

Our laboratories conduct post-market monitoring and compliance testing, investigations, and reviews, as well as market authorisation assessment of therapeutic goods.

A risk management approach, consistent with *ISO 31000: Risk Management principals and guidelines,* is used to identify products with a higher risk of not complying with the required quality standards. This risk-based, targeted approach to testing is reflected in the failure rates reported in the table below.

Laboratory testing results are made available through the [*Database of TGA Laboratory Testing Results*](https://www.tga.gov.au/ws-labs-index). In addition to the routine publication of testing outcomes, we are increasingly publishing more detailed reports related to specific testing projects undertaken within our testing program.

A significant rise in the number of Medical Devices tested was observed during the reporting period. This was predominantly due to the testing of face masks and respirators included on the ARTG. Further information regarding this testing can be found on the [testing of face masks and respirators webpage](https://www.tga.gov.au/testing-face-masks-and-respirators).

An increase in the failure rate of Complementary Medicines was also observed in this period when compared to 2020-21, however this result is affected by the lower number of samples tested over the reporting period due to the pandemic. Similarly, an increase in the failure rate of Pacific Medicines Testing Program samples was observed in 2021-22 as compared to 2020-21, and this is most likely due to the specific targeting of testing, as well as the inclusion of testing of face masks.

The significant increase in workloads due to the COVID-19 pandemic have affected compliance with usual timeframe targets.

Table 76 Samples and products tested by type of therapeutic good and percentage which failed

|  |  |
| --- | --- |
| 2020-21 | 2021-22 |
|  | | **July to June** | |
| Therapeutic good type | | | |
| Prescription medicines | Total | 869 | 900 |
| % fail | 2% | 2% |
| OTC medicines | Total | 81 | 0 |
| % fail | 6% | 0% |
| Complementary medicines a | Total | 18 | 53 |
| % fail | 39% | 9% |
| Medical devices | Total | 827 | 1,738 |
| % fail | 52% | 35% |
| External a | Total | 22 | 8 |
| % fail | 9% | 13% |
| Pacific Medicines Testing Program | Total | 53 | 26 |
| % Fail | 43% | 9% |
| Unregistered b | Total | 230 | 371 |
| % fail | 32% | 73% |
| Total samples (excluding AHQ samples) | | 2,100 | 3,096 |
| Total samples c | | 2,684 | 3,449 |
| Percentage fail | | 27% | 30% |
| Total number of products tested d | | 1,003 | 1,345 |

a Performed on request for overseas regulators, and encompasses medicines and medical devices.

b ‘Unregistered’ refers to products that meet the definition of therapeutic goods but are not included on the ARTG or otherwise specifically exempted from this requirement in the legislation. This often includes adulterated complementary medicines or counterfeit products.

c Includes accreditation, harmonisation and quality control (AHQ) samples.

d We may test a number of samples of each product per reporting period.

Table 77 Samples that failed laboratory testing by reason for July 2021 to June 2022

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Medical devices | OTC medicines | Prescription medicines | Unregistered products | Complementary medicines | External | Pacific Medicines Testing Program | Total  (% fail) |
| Contamination | 2 | 0 | 0 | 211 | 1 | 0 | 1 | 215 (7%) |
| Formulation | 0 | 0 | 2 | 33 | 4 | 1 | 6 | 46 (1%) |
| Label and packaging deficiencies | 109 | 0 | 0 | 0 | 0 | 0 | 0 | 109 (4%) |
| Performance a | 504 | 0 | 0 | 0 | 0 | 0 | 2 | 506 (16%) |
| Physical or mechanical properties | 1 | 0 | 15 | 0 | 0 | 0 | 0 | 16 (<1%) |
| Unregistered | 0 | 0 | 0 | 27 | 0 | 0 | 0 | 27 (<1%) |
| Total | 616 | 0 | 17 | 271 | 5 | 1 | 9 | 919 (100%) |

a Performance means failure of the product to meet criteria/requirements critical to the intended purpose of the goods.

Table 78 Batch release and export certification

|  |  |
| --- | --- |
| 2020-21 | 2021-22 |
|  | **July to June** | |
| Batch releases and certifications | | |
| Batch release a | 656 | 588 |
| Export certification b | 18 | 18 |

a Evaluation of batch release documentation for vaccines, biotechnology and blood products.

b Certification of biological products being exported from Australian manufacturers to overseas markets.

The TGA provides the World Health Organisation-approved certificates for batches of biological products to be exported by Australian manufacturers to overseas markets.

Table 79 Target timeframes in working days for laboratory testing by priority and testing type

|  |  |  |  |
| --- | --- | --- | --- |
| Priority of testing | Biochemical/  chemical testing | Microbiological testing | Medical device testing |
| Urgent a | 20 (95% of target times to be met) | 40 (95% of target times to be met) | 20 (95% of target times to be met) |
| Priority | 40 (80% of target times to be met) | 50 (80% of target times to be met) | 40 (80% of target times to be met) |
| Routine | 50 | 50 | 50 |

a Testing on products linked to potential public safety concerns are assigned to the ‘Urgent’ testing category. Urgent testing may impact on the timeframes for priority and routine testing. Priority is given to testing of products with the highest risk of a quality deficiency.

Table 80 Compliance with testing timeframes a for July 2021 to June 2022

|  |  |  |
| --- | --- | --- |
|  | Priority | Number (% of Total) |
| Therapeutic good type b | | |
| Medical devices | Routine | 1,733 (57%) |
| Priority | 5 (80%) |
| Urgent | 0 (0%) |
| OTC medicines | Routine | 0 (0%) |
| Priority | 0 (0%) |
| Urgent | 0 (0%) |
| Prescription medicines | Routine | 23 (87%) |
| Priority | 4 (25%) |
| Urgent | 0 (0%) |
| Complementary Medicines | Routine | 16 (75%) |
| Priority | 37 (46%) |
| Urgent | 0 (0%) |
| Unregistered products | Routine | 80 (65%) |
| Priority | 281 (77%) |
| Urgent | 10 (20%) |

a Samples involving complex biological assays are excluded from the target turnaround timeframes.

b Low numbers of samples within categories may affect compliance percentages.

Table 81 Face Mask Testing and percentage which were non-compliant by reason

The Laboratories received 1,552 samples of face masks for testing. Of these, 52 were from the National Medical Stockpile and 42 were from State/Territory Health Departments.

Testing for face masks varies based on the product type and claims and can include assessments for Design & Quality, Fluid Resistance, Particulate Filtration Efficiency, and Sterility.

|  |  |  |
| --- | --- | --- |
|  | **Tested** | **% Non-compliant** |
| Design and Quality | 1,407 | 13% |
| Fluid Resistance | 1,130 | 35% |
| Particulate Filtration Efficiency | 374 | 26% |
| Sterility | 20 | 15% |

1. 15. Regulatory Compliance

The TGA conducts compliance and enforcement activities against a risk-based compliance framework. A range of tools are utilised to encourage compliance and address non-compliance including education and guidance, warnings, the issue of infringements, and/or product suspensions or cancellations. Investigations may also result in criminal or civil court proceedings. For advertising related compliance and enforcement outcomes and activities, please refer to the [2021-22 Advertising Compliance Annual Report](https://www.tga.gov.au/resources/publication/publications/therapeutic-goods-advertising-compliance-2021-22-annual-report).

Table 82 Number of compliance actions taken against completed investigations

|  |  |  |
| --- | --- | --- |
|  | 1. 2020-21 | 1. 2021-22 |
|  | 1. **July to June** | |
|  | 1. **Number (% of Total)** | |
| Completed investigations |  |  |
| 1. No offence identified | 1. 508 (12%) | 1. 357 (4%) |
| 1. Goods released under Personal Import Scheme | 1. 290 (7%) | 1. 285 (3%) |
| 1. Referred internally | 1. 22 (<1%) | 1. 27 (<1%) |
| 1. Referred to external agency | 1. 95 (2%) | 1. 227 (3%) |
| 1. Warning letters issued a | 1. 3,072 (75%) | 1. 8,015 (89%) |
| 1. Infringement notices b | 1. 89 (2%) | 1. 74 (<1%) |
| 1. Referred to the Commonwealth Director of Public Prosecutions | 1. 2 (<1%) | 1. 1 (<1%) |
| 1. Criminal prosecution | 1. 2 (<1%) | 1. 2 (<1%) |
| 1. Total c | 1. 4,088 (100%) | 1. 8,988 (100%) |
| 1. Units of goods referred to ABF for destruction d | 1. 1,197,300 | 1. 5,137,491 |

a The category ‘warning letters issued’ can include goods destroyed as prohibited imports and goods re-exported.

b For infringement notices issued for advertising contraventions please refer to the [Therapeutic Goods Advertising Compliance Annual Report 2021-22.](https://www.tga.gov.au/resources/publication/publications/therapeutic-goods-advertising-compliance-2021-22-annual-report)

c There can be multiple actions per case resulting in a higher total figure than shown in finalised cases below.

d Units refers to single dosage unit e.g. 1 tablet, 1 capsule, 1 tub of powder or a single device.

Table 83 Regulatory compliance investigations by number

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Compliance cases a | | |
| Cases received | 4,215 | 11,501 |
| Cases active b | 919 | 2,213 |
| Cases finalised b | 4,049 | 8,625 |

a These figures are based on case numbers and not actions taken or offence types.

b Cases may not have been received in the same financial year.

Table 84 Number of different products investigated

|  |  |  |
| --- | --- | --- |
|  | 1. 2020-21 | 1. 2021-22 |
|  | 1. **July to June** | |
|  | 1. **Number (% of Total)** | |
| Therapeutic good type | | |
| 1. Prescription medicines (Schedule 4 and Schedule 8) | 1. 4,795 (73%) | 1. 19,296 (84%) |
| 1. Schedule 9 medicines | 1. 12 (<1%) | 1. 5 (<1%) |
| 1. Schedule 10 medicines | 1. 47 (<1%) | 1. 17 (<1%) |
| 1. Medical devices | 1. 421 (6%) | 1. 442 (2%) |
| 1. Complementary and homoeopathic medicines | 1. 430 (7%) | 1. 196 (<1%) |
| 1. OTC medicines | 1. 58 (<1%) | 1. 42 (<1%) |
| 1. Biological and blood products | 1. 3 (<1%) | 1. 3 (<1%) |
| 1. Other a | 1. 846 (13%) | 1. 3,076 (13%) |
| 1. Total b | 1. 6,612 (100%) | 1. 23,077 (100%) |

a Due to system technical issues, some investigations were unable to be categorised by therapeutic good type.   
b Multiple therapeutic goods types may appear in a single case.

Table 85 Regulatory compliance investigations by special interest categories

|  |  |  |
| --- | --- | --- |
|  | 1. 2020-21 | 1. 2021-22 |
|  | 1. **July to June** | |
|  | 1. **Number (% of Total)** | |
| Compliance investigation category | | |
| 1. Unregistered | 1. 9,582 (98%) | 1. 21,847 (95%) |
| 1. Registered | 1. 186 (2%) | 1. 151 (<1%) |
| 1. Counterfeit product | 1. 22 (<1%) | 1. 1,079 (5%) |
| 1. Total a | 1. 9,790 (100%) | 1. 23,077 (100%) |

a There can be multiple special interest categories in a single case.

Table 86 Number of offence types related to completed cases

|  |  |  |
| --- | --- | --- |
|  | 1. 2020-21 | 1. 2021-22 |
|  | 1. **July to June** | |
|  | 1. **Number (% of total)** | |
| Offence type | | |
| Import | 1. 4,278 (97%) | 1. 9,237 (97%) |
| Export | 1. 11 (<1%) | 1. 3 (<1%) |
| Manufacture | 1. 4 (<%) | 1. 4 (<1%) |
| Supply | 1. 137 (3%) | 1. 261 (3%) |
| Advertising | 1. 0 (0%) | 1. 4 (<1%) |
| Total completed a | 1. 4,430 (100%) | 1. 9,509 (100%) |

a  There can be multiple offences in a single case.

1. 16. Pharmacovigilance Inspection Program

Table 87 Pharmacovigilance Inspection Program inspections undertaken and deficiencies identified

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Compliance investigation category | | |
| Total inspections completed | 6 | 10 |
| Total with completed findings | 6 | 10 |
| Critical deficiencies a | 3 | 2 |
| Major deficiencies b | 27 | 32 |
| Minor deficiencies c | 15 | 28 |
| Average deficiencies per inspection | 0.5 critical  4.5 major  2.5 minor | 0.2 critical  3.2 major  2.8 minor |

a A deficiency in pharmacovigilance systems, practices or processes that adversely affects the rights, safety, or well-being of patients or that poses a potential risk to public health or that represents a serious violation of applicable legislation and guidelines. Deficiencies classified as critical may include a pattern of deviations classified as major. A critical deficiency also occurs when a sponsor is observed to have engaged in fraud, misrepresentation, or falsification of data. Deficiencies are classified by the assessed risk level and may vary depending on the nature of medicine. In some circumstances an otherwise major deficiency may be categorised as critical.

b A deficiency in pharmacovigilance systems, practices or processes that could potentially adversely affect the rights, safety, or well-being of patients or that could potentially pose a risk to public health or that represents a violation of applicable legislation and guidelines. Deficiencies classified as major may include a pattern of deviations classified as minor.

c A deficiency in pharmacovigilance systems, practices or processes that would not be expected to adversely affect the rights, safety, or well-being of patients. A deficiency may be minor either because it is judged as minor or because there is insufficient information to classify it as major or critical.

1. 17. Reporting of Medicine Shortages

Table 88 Number of medicine shortage reports a by shortage reason

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
|  | **Number (% of Total)** | |
| Shortages Reported | | |
| New – Commercial changes | 36 (3%) | 37 (3%) |
| New – Discontinuation | 135 (11%) | 177 (15%) |
| New – Manufacturing related | 445 (36l%) | 666 (56%) |
| New – Other b | 416 (33%) | 0 (0%) |
| New – Product recall | 2 (<1%) | 5 (<1%) |
| New – Unexpected increase in demand | 202 (16%) | 135 (11%) |
| New – Unexpected increase in demand due to other sponsors unable to supply | 3 (<1%) | 42 (4%) |
| New – Transport / Logistic issues / Storage capacity issues | 8 (<1%) | 122 (10%) |
| New – Seasonal depletion of stock | 0 (0%) | 6(<1%) |
| Total | 1,247 (100%) | 1,190 (100%) |

a New reports only, does not include updates of previously reported shortages.

b ‘Other’ was removed as a shortage reason from 1 June 2021.

Table 89 Number of medicine shortage notifications processed

|  |  |  |
| --- | --- | --- |
|  | 2020-21 | 2021-22 |
|  | **July to June** | |
| Notifications processed | | |
| New | 1,247 | 1,190 |
| Update a | 3,978 | 3,386 |
| Total | 5,225 | 4,576 |

a Updates of previously reported shortages, including updates to ‘Resolved’ status. Mandatory reporting of all shortages of prescription medicines and select over-the-counter medicines commenced 1 January 2019.

1. Please refer to Table 38, Appendix 7.1. [↑](#footnote-ref-2)
2. Please refer to Table 1, Appendix 1.1. [↑](#footnote-ref-3)
3. Please refer to Table 3, Appendix 1.2. [↑](#footnote-ref-4)
4. Please refer to Table 12, Appendix 2.2.1. [↑](#footnote-ref-5)
5. Please refer to Table 9, Appendix 2 for a glossary of application categories, and to Table 13, Appendix 2.2.2 for the statistics. [↑](#footnote-ref-6)
6. Please refer to Table 12, Appendix 2.2.1. [↑](#footnote-ref-7)
7. Please refer to Table 11, Appendix 2.1. [↑](#footnote-ref-8)
8. Please refer to Table 11, Appendix 2.1. [↑](#footnote-ref-9)
9. Please refer to Table 16, Appendix 3. [↑](#footnote-ref-10)
10. Please refer to Table 20, Appendix 5.1. [↑](#footnote-ref-11)
11. Please refer to Table 24, Appendix 5.5. [↑](#footnote-ref-12)
12. Please refer to Table 23, Appendix 5.4. [↑](#footnote-ref-13)
13. Please refer to Table 22, Appendix 5.3. [↑](#footnote-ref-14)
14. Please refer to Table 56, Table 57 and Table 58, Appendix 11.1 for SAS B approvals, and to Table 63, Appendix 11.3 for AP approvals. [↑](#footnote-ref-15)
15. Please refer to Table 58, Appendix 11.1. [↑](#footnote-ref-16)
16. Please refer to Table 39, Appendix 8.1.1. [↑](#footnote-ref-17)
17. Please refer to Table 41, Appendix 8.1.3. [↑](#footnote-ref-18)
18. Please refer to Table 76, Appendix 14. [↑](#footnote-ref-19)
19. Please refer to Table 68, Appendix 12.2. [↑](#footnote-ref-20)
20. Please refer to Table 66, Appendix 12.1. [↑](#footnote-ref-21)
21. Please refer to Table 69, Appendix 12.3. [↑](#footnote-ref-22)
22. Please refer to Tables 72-75, Appendix 13. [↑](#footnote-ref-23)
23. Please refer to Table 38, Appendix 7.1. [↑](#footnote-ref-24)
24. Please see Table 28, Appendix 5.8. [↑](#footnote-ref-25)
25. Please refer to Table 87 in Appendix 16. [↑](#footnote-ref-26)